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ABSTRACT 
Malignant melanoma of the skin is one of the most rapidly increasing cancers in many 
western countries, including Sweden. This incidence rise is mainly attributed to sun-seeking 
habits with increased intermittent UVR exposure, a major risk factor for melanoma. Family 
history is another important risk factor for melanoma, approximately 10% of all cases occur 
in melanoma families. Germline mutations in the tumor suppressor gene CDKN2A occur in 
5–25% of familial melanoma cases. A single founder mutation, p.Arg112dup, accounts for 
the majority of CDKN2A mutations in Swedish carriers. Individuals with p.Arg112dup and 
several other CDKN2A mutations also have an increased risk of developing pancreatic 
carcinoma, but less has been known about carriers’ risks of other cancers. High-risk 
melanoma associated mutations, other than CDKN2A have yet only been identified in a small 
number of families, in the majority of melanoma families, the cause for heredity still remains 
unsolved. So far, there have been no studies investigating cancer risks in CDKN2A wild type 
(wt) melanoma families. Also research addressing survival functions in melanoma families 
have until now been lacking. Compared to cutaneous melanoma, uveal melanoma is a much 
rarer disease, where no incidence rise or any strong association with UVR exposure has been 
observed. Familial uveal melanoma cases exist, but are rare. Until 2-3 years ago, there was no 
germline gene mutation known to be associated with uveal melanoma.  
In papers I-III cancer risks and prognosis in familial melanoma kindreds, depending on 
CDKN2A mutation status is estimated by linkage of personal identity numbers of familial 
melanoma kindreds to several Swedish Registries, including the Multi-generation Registry 
and the Cancer Registry. Paper IV is a family-based association study employing whole-
exome sequencing to identify a disease associated mutation in a rare uveal melanoma family.  
Carriers of the Swedish founder mutation in CDKN2A and also carriers’ un-genotyped first- 
and second-degree relatives were found to have significantly increased risks of melanoma, 
pancreatic cancer, and cancers in respiratory and upper digestive tissues. Ever-smoking 
carriers had, compared to never-smoking carriers, significantly higher risks of these non-
melanoma cancers. Familial melanoma cases with no CDKN2A mutation and their first-
degree relatives had significant increased risk of melanoma and of sqaumous cell skin cancer, 
but not of other cancers. CDKN2A mutated melanoma cases had compared to CDKN2A wt 
cases, after adjusting for age, sex and tumor thickness, significantly increased mortality from 
melanoma and from non-melanoma cancers. Compared to matched sporadic melanoma cases, 
CDKN2A mutated cases had significantly increased mortality from both melanoma and non-
melanoma cancers, while CDKN2A wt cases had no mortality increase compared to sporadic 
cases. In the uveal melanoma family, a disease segregating mutation was found in the BAP1 
tumor suppressor gene on chromosome 3p21. 
These studies demonstrate different risk spectra among familial melanoma kindreds. 
CDKN2A mutation carriers have besides from melanoma high risks of tobacco-related 
cancers and have worse survival from both melanoma and other cancers compared to non-
carriers. Familial melanoma cases with no CDKN2A mutation have increased risks only of 
skin cancers and have survival comparable to sporadic melanoma cases. BAP1 mutation 
carriers have high risks of uveal melanoma and also of cutaneous melanoma and of other 
cancers. These findings further justify CDKN2A mutation testing of melanoma family 
members in the clinical setting where the mutation status should determine the follow-up 
routines in affected families. Members of CDKN2A wt melanoma families require counseling 
and screening aimed at prevention and earlier detection of skin cancers while CDKN2A 
mutation carriers require in addition to dermatologic surveillance, follow-up for non-skin 
cancers and also close follow-up for melanoma recurrences. BAP1 mutation carriers require 
ophthalmologic, oncologic and dermatologic surveillance. 
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1 MALIGNANT MELANOMA OF THE SKIN 
1.1 HISTORICAL PERSPECTIVE 
1.1.1 Early observations 
Although melanoma is not a new disease, written or archeological evidence for its occurrence 
before the 19th century is scarce. At a lecture in 1804 in Paris, the French physician René 
Leannec (1781-1826) was the first to describe melanoma as a disease entity1. He described 
dark tumors in lungs, lymph nodes, liver, brain, stomach and peritoneum. He referred to the 
condition as melanosis, from the Greek word melas, which means black. He further noted 
that melanosis of the lungs was not associated with the same hectic fever as tuberculosis, that 
was a common condition at the time. Laennec is also renowned as the inventor of the 
stethoscope2. The English general practitioner William Norris (1792-1877) was the first to 
study melanoma in depth, and made several principal observations on the pathology, 
epidemiology and management of melanoma 3,4. He described a correlation between moles, 
primary melanomas and disseminated melanoma. He noted that the degree of pigmentation 
varied and some lesions could be amelanotic. Norris observed that his patients had fair 
complexions and light colored hair. He also noted cases with family history of melanoma and 
multiple moles and suggested a probable hereditary predisposition. He also advocated wide 
excisions of the tumor and surrounding tissues.  
1.1.2 Establishment of surgical management principles 
The first known formal statement of advanced melanoma as untreatable was published in a 
book written in 1840 by the English surgeon Samuel Cooper (1780-1848) who remarked “no 
remedy is known for melanosis. The only chance for benefit depends upon the early removal 
of the disease by operation, when the situation of the part affected will admit of it”5. The 
surgeon William Sampson Handley (1872-1962) advocated in 1907 at lectures for the Royal 
College of Surgeons of England, the importance of a wide local excision of the primary 
melanoma with a circular >10 cm incision of the skin and excision of underlying deep fascia 
and muscle in combination with regional lymph node dissection and amputation in selected 
cases6. Handley’s recommendations formed the basis for melanoma treatment well into the 
1980s when trials offered further refinement of the surgical approaches, such as defining 
proper surgical margins for primary melanoma and the utility of lymph node dissection7.  
1.1.3 Naissance of histological staging criteria predicting prognosis 
A pioneer in the study on appropriate surgical margins for primary melanomas was the 
American pathologist Alexander Breslow (1928-1980)8. He had also, in a series of papers, the 
first published in 1970, showed that the most important single prognostic parameter of 
primary melanoma was tumor thickness, a better predictor of metastasis and survival than any 
other parameter, such as growth pattern, surgical margins or level of invasion9,10. The 
Breslow tumor thickness became an important stratification criterion, and is since 2002 the 
primary criterion for primary tumor (T) classification in the TNM classification of the 
2                                                           
    
 
American Joint Committee on Cancer (AJCC) melanoma staging system11. The American 
pathologist Wallace H Clark, Jr (1924-1997) had in 1969, together with colleagues delineated 
the “Clark levels” of invasion, which were the primary stratification criterion in earlier AJCC 
staging schemae for primary melanoma12. However, it became evident that Clark's level has a 
lower predictive value, is less reproducible, and is more operator-dependent as compared 
with Breslow's depth13. Thus, in the current (2010) AJCC staging system, Clark level is no 
longer recommended as a staging criterion14. Clark also described 3 major histological types 
in melanoma, superficial spreading melanoma (SSM), nodular melanoma (NM) and lentigo 
maligna melanoma (LMM)15. Moreover, Clark described the dysplastic nevus, also known as 
the clinically atypical mole, Clark’s nevus or B-K mole (B and K; first initials in last names 
of melanoma families described by Clark et al. 1978) as a precursor and a marker of 
increased risk of melanoma among familial melanoma kindreds16. The Australian pathologist 
Vincent J McGovern (1915-1983) wrote landmark papers on the significance of tumor 
thickness, ulceration, mitotic rate and regression and their relationship to prognosis17-19. He 
had an important role in the implementation of classification systems and melanoma 
nomenclature. Tumor thickness, mitotic rate and ulceration are today all considered 
significant staging criteria and are included in the current AJCC staging system14,20. 
McGovern was further, in the late 1950s, one of the first to call attention to the role of 
sunlight in the development of melanoma21.  
1.1.4 Emergence of systemic therapies 
During the 1970s chemotherapy began to make inroads in the treatment of disseminated 
melanoma. Studies of the alkylating agent dacarbazine (dimethyl traozeno imidazole 
carboxamide; DTIC) showed response rates up to 30%, which lead to the 1976 Food and 
Drug Administration (FDA) approval of this drug as the first systemic therapy for metastatic 
melanoma22. Since other single or polychemotherapy agents have failed to show additional 
clinical benefit, dacarbazine, is still, together with its oral analog, temozolamide, the only 
FDA approved chemotherapeutic agent for the treatment of metastatic melanoma22. In 
parallel with the entrance of melanoma chemotherapy treatments, important observations on 
immunological responses to melanoma were made, such as the description of melanoma 
antigens in 197423. This marked the beginning of an elongated quest to identify immune 
based antitumoral regimens, leading to the FDA approval of adjuvant therapy in stage III 
melanoma with high-dose interferon in 1996 and of high-dose bolus IL-2 for advanced 
melanoma in 1998 7.Today, these drugs are in many countries, including Sweden, not 
considered part of standard melanoma treatment, but the translational discoveries on tumor 
immunology paved the way for subsequent discovery of targeted immune modulating 
therapies that, compared to standard chemotherapy, showed superior outcomes in 
randomized studies24-26. This has lead to the FDA approval of the immune checkpoint 
inhibitors ipilimumab in 2011 and of pembrolizumab and nivolumab in 201427. The Human 
Genome project, that initiated in 1990 and was declared complete in 2003, significantly 
contributed to the ability to perform large-scale DNA studies28. One of many results from 
this was the identification of high-frequency mutations in the BRAF and NRAS oncogenes29 
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that has subsequently lead to the discovery of selective inhibitors targeting the Ras-Raf-
MEK-ERK pathway that is often constitutionally activated in melanoma30,31. The BRAF 
inhibitors vemurafenib and dabrafenib were FDA approved in 2011 and 2013, respectively 
and the MEK-1 inhibitor trametinib in 201327,32. Currently, there are numerous ongoing 
studies investigating various targeted therapy regimens for metastatic melanoma33.  
1.2 EPIDEMIOLOGY 
1.2.1 Population trends 
The incidence of melanoma of the skin has been increasing in most Caucasian populations in 
the last decades34. The increase in melanoma incidence is mainly ascribed to changes in 
attitudes toward sun bathing and tanning in westernized countries, but ageing populations as 
well as higher detection rates are also contributing factors34. The highest melanoma 
incidences are observed in countries predominated by fair-skinned populations and sunny 
climates such as in Australia and New Zeeland35 (Table 1). Countries predominated by 
African, Asian and Hispanic populations generally have much lower incidence rates35. In 
Sweden there has been a steep increase in melanoma incidence since the 1970s (Figure 1), 
with close to 5% yearly increase in the last decade (there are differences in the Swedish 
incidence numbers displayed, in Table 1 where the age standard incidence is based on the 
world standard population, whereas in Figure 1, the age-standardized incidence is based on 
the Swedish population, that is considerably older than the world population)36,37. In recent 
years, several high-incidence countries have seen a leveling off in the melanoma incidence, 
implying a possible beginning of a decline34,36. In Sweden, there is yet no sign of such a turn 
in the incidence, in 2014 there were over 3.723 melanomas diagnosed, compared to 3.358 in 
2013 (C. Ingvar, personal communication, October 1st 2015). The massive increase in 
melanoma incidence has not been followed by the same increase in mortality (Figure 1), only 
a subtle increase has been observed, probably explained mostly by increased preventive 
measures leading to earlier detection of tumors, but also by improvements in the management 
of the disease. 
1.2.2 Age and sex 
In 2013, 3.358 invasive melanomas (1.663 in women and 1.695 in men) were diagnosed in 
Sweden (current population 9.8 million inhabitants), which represents 5.5% of all diagnosed 
cancers36. Melanoma is the 5th most common cancer among women and 6th most common 
among males in Sweden. In both males and females, melanoma incidence increases with 
increasing age. Although the total numbers of melanomas, diagnosed in men and women, are 
almost equal, the age curves are differing, with earlier onset in women and higher incidences 
in older males (Figure 2)36.  
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Table 1. Melanoma incidence* in different countries in 2012 per 100,000 inhabitants** 
EUROPE     AFRICA/ASIA     AMERICA/OCEANIA 
Netherlands 19.4   South Africa 4.5   New Zealand 35.8 
Denmark 19.2   Russia 4.1   Australia 34.9 
Norway 18.8   Turkey 2.1   USA 14.3 
Sweden 18.0   Turkmenistan 1.2   Canada 9.6 
UK 14.6   Iran 0.8   Papua New-Guinea 4.2 
Ireland 13.7   Afghanistan 0.7   Uruguay 4.1 
Iceland 13.7   Japan 0.6   Argentina 2.9 
Finland 12.6   China 0.6   Brazil 2.8 
Germany 11.4   Morocco 0.4   Costa Rica 2.3 
Italy 11.4   Saudi Arabia 0.3   Chile 1.5 
France 10.2   India 0.2   Jamaica 0.9 
Spain 6.9   Ethiopia 0.1   Cuba 0.8 
Greece 2.4   Sri Lanka 0.1   Haiti 0.1 
*Based on data from WHO, IARC, Globocan 2012 (http://globocan.iarc.fr/Pages/Map.aspx) 
**Age-standardized incidence rates based on world standard population    
 
 
Figure 1. Age-standardized melanoma incidence and mortality per 100,000 inhabitants in Sweden 
1970-2013. Reproduced from Swedish National Board of Health and Welfare.  
 
 
Figure 2. Age specific melanoma incidence in 1991-93 and 2011-13 per 100,000 male and female 
inhabitants, 3-year mean value. Reproduced from Swedish National Board of Health and Welfare.  
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1.3 RISK FACTORS FOR MELANOMA OF THE SKIN 
1.3.1 Ultraviolet radiation 
Today, there is a strong consensus regarding ultraviolet radiation (UVR) being the most 
significant environmental risk factor for malignant melanoma of the skin38. UVR is divided 
into the longer wavelength UV-A, the intermediate wavelength UV-B, and the shorter 
wavelength UV-C, which is completely absorbed by the atmospheric ozone layer and does 
not reach the surface of the earth. UV-A radiation reaches deeply into the skin causing 
tanning and ageing of the skin, while UV-B radiation is absorbed by the superficial epidermis 
causing skin reddening and sunburn39. The main carcinogenic effect is believed to be from 
the UV-B radiation, but UV-A has also been shown to have a carcinogenic effect40. The 
carcinogenic effects of UVR is believed to be due to DNA damage and mutations in the 
melanocytes, and also due to immunologic and inflammatory processes, growth stimulation 
and oxidative stress41. The main source of UVR is the sun, where UV-A radiation accounts 
for ~95% of the radiation reaching the earth’s surface. Sun beds are also a significant source 
of UVR in the population, before the 1980s such lamps could emit up to 40% of the highly 
carcinogenic UV-B radiation, while modern lamps have much lower percentages of UV-B, 
down to <0.1%, but this can vary greatly42. Sun lamps are generally believed to be a 
significant melanoma-causing carcinogen, particularly in young users. Sun lamp use is 
forbidden by law before the age of 18 years in many countries, but not yet in Sweden. 
Different patterns of UVR exposures during lifetime affects the histological melanoma 
subtypes that arise. Intermittent UVR exposures and sunburns, occurring for example at 
beach holidays in sunny countries, increase the risk of superficial spreading melanoma 
(SSM), which is the subtype of melanoma with the fastest growing incidence. Chronic UVR 
exposure, often occurring in outdoor workers, increases the risk of lentigo maligna melanoma 
(LMM) and also of non-melanoma skin cancers on chronically exposed sun-damaged skin39. 
UVR is classified as a Group 1 carcionogen by the International Agency for Research on 
Cancer (IARC)43. In the IARC Group 1, there are 117 listed agents that, beyond doubt, are 
carcinogenic to humans. There are many different types of carcinogenic agents such as 
chemicals, hormones, radiation, radioactive substances, chemotherapeutic agents, viruses and 
bacteria. The single largest environmental source of carcinogens in Group 1 is tobacco smoke 
with at least 20 substances listed as group 1 carcinogens, including polycyclic aromatic 
hydrocarbons (PAHs), aza-arenes, aromatic amines, N-nitrosamines and aldehydes43,44. While 
UVR and tobacco smoke derivates are both mutagenic, the mechanism of mutational 
processes differ and result in different signature mutations. UVR causes signature base pair 
C→T transitions, while tobacco smoke signatures can be recognized by C→A transitions45. 
Tobacco smoke is strongly associated with many cancers, but not with melanoma46. 
1.3.2 Pigmentation traits 
Pigmentation traits are important risk factors for melanoma, best illustrated by the high 
incidence differences between individuals of north-European descent compared to individuals 
6                                                           
    
 
of African or Asian descent (Table 1)35. In a large meta-analysis, where most participating 
centers were in countries dominated by Caucasian populations, it was found that blue or 
green eye color, red, blond or light hair color, high density of freckles, light skin color and 
photosensitivity where all associated with significantly increased risk for melanoma. The 
highest relative risk was seen for red vs. dark hair color, with a relative risk of 3.647. 
Pigmentation traits are determined by genetic variants in a set of different genes. Many of 
such pigmentation genes, such as the Melanocortin-1 Receptor (MC1R) and the Tyrosine 
(TYR) genes have variants, single nuclear polymorphisms (SNPs) that are known to be both 
indirectly (through pigmentation traits) and independently associated with ~1.1 - 5 fold risk 
increase for melanoma48-50. These genes are therefore called low-risk melanoma genes (in 
contrast to high-risk melanoma associated genes, such as CDKN2A). Other known 
pigmentation involved low-risk melanoma genes are ASIP and TYRP. SNPs in pigmentation 
genes are not only associated with increased risks of melanoma, but also with increased risks 
of non-melanoma skin cancers, in particular squamous cell skin cancer and basal cell skin 
cancer, while such SNPs are not associated with increased risks of non-skin cancers49.  
1.3.3 Familial predisposition 
It was early described that cutaneous melanoma sometimes occurs in blood related 
individuals4. It was noted that members of such families often had multiple atypical looking 
nevi. This condition was previously described by names such as dysplastic nevus syndrome 
(DNS), familial atypical multiple mole melanoma (FAMMM) or B-K mole syndrome16. 
However, it has become apparent that in some families with multiple cases of melanoma, 
members do not have the characteristic multiple nevi, and also there are individuals and 
families that have many nevi without an association with melanoma51,52. The best predictor 
of melanomas risk is previous melanomas in two or more closely related family 
members53,54. Today the condition is commonly described simply as “familial melanoma”. It 
is estimated that approximately 10% of all cases of cutaneous malignant melanoma occur in 
melanoma families55-57. Familial predisposition is among the strongest known risk factors for 
melanoma, where affected members can have up to 90% life time risk to develop 
melanoma58. Mutations in the tumor suppressor gene CDKN2A are found in 5-25% of 
melanoma kindreds, where mutation frequency varies between regions and selection criteria 
used (Table 2)53,59. In countries, such as Australia, the fraction of mutation positive families 
is lower, probably explained by the larger impact of UVR exposures on high melanoma 
incidences in such regions. Families with more melanomas diagnosed and more affected 
individuals, as well as younger ages of onset have higher incidences of CDKN2A mutations.  
 
Table 2. Percentage of CDKN2A mutation carrying families, depending on different features of the families*
Numbers of diagnosed melanoma tumors within a family, 2 vs. ≥3 7% vs. 17%
Numbers of melanoma affected individuals in family, 2 vs. ≥3 8% vs. 27%
Numbers of melanoma and pancreatic cancer diagnoses in family, 2 vs. ≥3** 10% vs. 65%
Origin of families, Australia vs. North-America vs. Europe*** 20% vs. 45% vs. 57%
Median age at diagnosis of melanoma, >50 vs. 40-50 vs. <40 *** 12% vs. 32% vs. 54%
*Adapted from Leachman et al. J Am ACAD Dermatol 2009 and Goldstein et al. J Med Genet 2007
**Only families with pancreatic cancer. ***Only families with ≥3 melanoma cases
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1.4 STAGING, CLASSIFICATION AND PROGNOSIS 
1.4.1 AJCC melanoma staging system 
The most recent AJCC melanoma staging system was published in the 7th edition of the 
AJCC Cancer Staging Manual in 201014. The staging criteria are based on prospective data 
on 30,946 patients with stages I, II, and III melanoma and 7,972 patients with stage IV 
melanoma. For classification of the primary melanoma, tumor thickness, ulceration and 
mitotic grade are staging criteria (Table 3). Staging criteria for nodal metastasis is the 
number of affected lymph nodes and presence of micro- or macrometastases or in 
transit/satellite metastases. Staging criteria for distant metastases are distant skin or nodal 
metastasis (M1a), lung metastasis (M1b), other visceral metastasis (M1c) and/or elevated 
lactate dehydrogenase (M1c). Figure 1 shows how the defined staging criteria (Table 3-4) 
correlate with prognosis in the AJCC cohort. In stage I melanoma the five year survival rate 
is high, 92-97%. In stage II melanoma the five year survival goes down to 53-81% and in 
stage III melanoma, to 40-78%. The five year survival rate in stage IV melanoma is 
extremely low, only 10-20%. 
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Figure 3. Survival curves of patients in the AJCC Staging Database, comparing the different T 
categories (A) and the stage groupings for stages I and II melanoma (B). For patients with stage III 
disease, survival curves are shown comparing the different N categories (C) and the stage groupings 
(D). Survival curves of patients with metastatic melanomas at distant sites, subgrouped by the site of 
metastatic disease (E) and by serum lactate dehydrogenase (LDH) levels (F). Reproduced, with 
permission, from Balch et al. J Clin Oncol 2009.  
 
1.4.2 Histologic subtypes of melanoma 
For melanoma of the skin, the following main growth patterns have been described; 
superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nodular 
melanoma (NM) and acral lentiginous melanoma (ALM) (Table 5)15,60. In addition, rarer 
subtypes exist, such as desmoplastic, verrucous, Spitzoid melanoma and malignant blue 
nevus39. SMM tumors, characterized by their initial radial growth pattern, often arising in 
preexisting nevi, typically occur in somewhat younger individuals on intermittently UVR 
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exposed locations, such as on the trunk, arms and legs39,61. NM tumors are characterized by 
their vertical growth pattern that is not preceded by a radial growth phase, as in SSM tumors. 
Mean age of diagnosis of NM tumors is higher than of SSM, but lower than of LMM. NMs 
can occur at any location, often in the head and neck area. LMM are slowly evolving tumors, 
often occurring in older individuals in chronically sun exposed areas on the face, ears and 
back of hands. ALMs are prominent in black and Asian populations and occur in the palms 
and soles, fingers, nail bed and also in mucosal membranes. Survival is considered similar 
for patients with SSM and NM tumors, while outcomes are more beneficial in LMM 
patients, but poorer in ALM patients39. In SSM and NM tumors, mutations in the BRAF gene 
are seen in 50-60% and in NRAS in 20-30% of cases62,63. In LMM and ALM tumors, KIT 
mutations are seen in 10-30% of cases62,64. CDKN2A mutations are seen in 10-15% of 
tumors, irrespectively of histologic subtype62.  
 
1.4.3 Other tumor specific prognostic factors 
Of tumor specific prognostic factors, the most relevant known today are included in the 
AJCC staging system. Anatomic site of the melanoma has also been shown to be an 
independent prognostic marker, with worse survival in patients with melanoma in the head 
and neck area, trunk, palms/soles and nailbeds65. The presence of tumor-infiltrating 
lymphocytes, which are believed to represent the immune reaction/response to the 
melanoma, has both been supported and refuted as a positive prognostic marker66,67. 
Melanoma regression with replacement of tumor tissue with fibrosis, degenerated melanoma 
cells, lymphocytic proliferation, and telangiectasia formation, is generally considered an 
adverse prognostic factor, but as with TILs, this has both been supported and rebutted68,69. 
1.4.4 Tumor-based genetic and molecular prognostic factors 
In the 1980s DNA flow cytometric analyses showed that aneuploidy correlated with poor 
prognosis in melanoma70. Melanomas are genetically instable tumors and have been 
demonstrated to be the tumor type that harbors the highest mutational load45. BRAF and 
NRAS mutations are common early and mostly mutually exclusive mutations in melanoma 
tumors63. Mutations in these genes are generally considered markers of poor prognosis, but it 
remains unresolved if they are independent prognostic factors71. Somatic mutations and 
deletions of the CDKN2A gene have also been associated with worse outcomes in melanoma 
patients72,73. Further, expression analyses have shown that expression levels of ~1,500 
distinctive genes reveals “low- and high-grade” signatures that predict survival in all stages 
of melanoma74,75. 
Table 5. Main melanoma growth patterns: Epidemiological, clinical, molecular and prognostic features.
Incidence Main patient Typical anatomical UVR Prevalent Prognostic
in Sweden groups Location induced mutations Impact
SSM 61% Younger Trunk, arms, legs +++ (Intermittent exposure) BRAF/NRAS, CDKN2A ↔
NM 16% Old/young Any, head and neck area ++ (Intermittent exposure) BRAF/NRAS, CDKN2A ↔
LMM 7% Older Face, ears, back of hands +++ (Chronic exposure) KIT, CDKN2A ↑
ALM 1% Non- Palms/soles, fingers, (+) KIT, CDKN2A ↓
Caucasians nail beds, mucosa
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1.4.5 Host related prognostic factors 
In several studies, older age and male sex have been shown to be independent predictors of 
poor prognosis65,76. The intrinsic or extrinsic causality behind this remains unresolved, but 
hormonal and immunologic differences have been suggested, as well as social factors 
affecting the course of diagnosis and treatment in different groups77. Lower socioeconomic 
status as well as living alone are associated with later diagnosis of melanoma tumors, but also 
independently predict poorer prognosis78-80. On a molecular level, certain haplotypes of 
human leukocyte antigens (HLA) of the human major histocompatibility complex (MHC) 
have been shown to affect prognosis, probably reflecting different host-dependent immune 
responses to tumors81,82. Germline mutations in the tumor suppressor gene CDKN2A are 
among the strongest known inherited genetic risk factors of cutaneous melanoma, but until 
now it has been unresolved whether such mutations also affect prognosis.  
1.5 MELANOMA PREVENTION 
1.5.1 Primary prevention: Education campaigns 
Primary prevention aims to avoid the development of disease. In the early 1960s increasing 
knowledge began to emerge on the role of sunlight and ultraviolet radiation (UVR) in the 
development of melanoma of the skin. In Australia, where very high incidence rates for 
melanoma were observed, preventive actions were initiated in the 1960s83. In the 1980s 
coordinated regional or nationwide campaigns were introduced in Australia, the U.S. and 
many European countries, including Sweden83,84. The focus of such campaigns was, and is 
still, to increase awareness of skin cancer in the population and promote habits to diminishing 
UVR exposure and sunburns, such as wearing protective clothing, avoidance of sun exposure 
in the middle of the day, staying in the shade, use of sunscreen, avoidance of tanning parlors 
etc85. In spite of these preventive efforts, melanoma incidence has continued to rise steeply35. 
Recent leveling off, observed in some high incidence countries, hopefully marks the 
beginning of a turn in this trend.  
1.5.2 Secondary prevention: Skin cancer screening 
Secondary prevention aims at detecting and treating diseases early. Among the most 
extensive secondary preventive measures carried out so far, are the population based 
screening programs for breast and cervical cancer that are available in most developed 
countries. In most western countries, including Sweden, there are no organized nationwide 
screening programs for skin cancers. In many countries, national or regional health care 
services instead provide public information or campaigns to promote self skin exams. In this 
sense, the ABCDE criteria (Asymmetry, irregular Border, multiple Colors, Diameter >5-6 
mm, Evolving) have been used to aid the public to identify and seek medical assessment of 
suspicious lesions86.  
In the Schleswig-Holstein region in Germany, a population-based study started in 2003 with 
whole-body inspection by general practitioner and dermatologists85. This study showed that in the 
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following 5 years, melanoma and non-melanoma skin cancers were diagnosed at earlier stages 
and that the melanoma specific mortality significantly decreased compared to neighboring 
regions as well as in a nationwide comparison87. As a result of this, Germany was in 2008, the 
first (and is still the only) country to introduce skin cancer screening as a standard benefit of the 
general health insurances with biennial skin exams starting at age 35 years. A subsequent study 
was carried out to evaluate the outcomes in 2008-2012 of the Schleswig-Holstein intervention 
and the nationwide screening program88. In this period no decrease in melanoma mortality was 
seen compared to before the interventions and melanoma mortality in Germany did not differ 
from those observed in surrounding countries. While evaluation of this screening initiative will 
continue, as for now, the rationale for population-based programs is weak.  
In many countries, including Sweden, there are preventive programs aimed at identifying high-
risk individuals, in particular members of melanoma families or individuals with multiple 
primary melanomas. These individuals are subsequently enrolled in screening programs with 
regular dermatologic surveillance with total body photography and digital dermatoscopy. Such 
screening has been shown to result in high numbers of histopathologically dysplastic nevi being 
excised and a low incidence of melanomas, and that the melanomas that do arise have favorable 
prognostic characteristics54,89,90. The effect on survival outcomes from screening of high-risk 
groups has not yet been evaluated. 
1.5.3 Tertiary prevention: Melanoma follow-up 
Tertiary prevention aims at preventing progression and complications from a manifest disease. 
Follow-up of patients after the diagnosis of melanoma is, by definition, an example of this. 
Although follow-up is practiced at most oncology centers, there is no clear evidence of this 
resulting in a survival benefit91,92. Not either when blood tests or radiology exams are used as 
part of the follow-up program, does this seem to affect survival93,94. Of melanoma recurrences, 
over 80% manifest within the first three years after diagnosis of the primary tumor. In most 
cases it is, in fact, the patient him/herself that detects metastases or new primary melanomas95. 
As for now, the role of the follow-up is considered to be mainly psychosocial support for the 
patient by providing help and guidance to cope with the melanoma diagnosis. Also follow-up 
has a role to educate the patient to recognize symptoms and signs of melanoma recurrences 
and new primary melanomas. To enable quick medical assessments of such findings, the 
patient needs to have good access to the clinic where the follow-up is carried out. The follow-
up schedules differ between countries, and are mostly dependent on local traditions and 
preferences. In the Swedish clinical guidelines for melanoma management, it is recommended 
that stage 0-I melanoma patients receive a follow-up visit within 6 weeks after the operation 
with general information on the disease and education on UVR protection and self-exams, no 
further routine controls are recommended thereafter61. Stage II melanoma patients receive, in 
addition, yearly follow-up visits with clinical exams and education for three years. Stage III 
patients receive such follow-up visits biannually for three years. To enable good access to the 
follow-up clinic, all patients get a contact-nurse. With better treatments options for advanced 
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disease, and if adjuvant therapies emerge in the melanoma management, is possible that a 
more active approach in follow-up routines will be implicated. 
1.6 MANAGEMENT OF CUTANEOUS MELANOMA 
1.6.1 Surgery of primary melanoma  
Appropriate surgical management remains the most important life-saving treatment of 
cutaneous melanoma. As described earlier, before the extent of proper surgical margins had 
been determined, very large skin resections were common, requiring large skin grafts with 
substantial morbidity and poor cosmetic results. Today, multiple randomized studies have 
provided evidence for more limited surgical margins61. In the Swedish national guidelines for 
malignant melanoma, a wide local excision of skin and subcutaneous tissue is recommended. 
Surgical margins to a pigmented lesion should be at least 2 mm, to a melanoma in situ at least 
5 mm and to a thin melanoma (≤1.0mm), at least 10 mm and to a thick melanoma (>1.0 mm) 
at least 20 mm. In the head and neck area, due to the cosmetic and functional aspects, 10 mm 
are considered sufficient margins61. There is no evidence of a benefit of postoperative 
radiation at the operation site. 
1.6.2 Management of regional lymph node involvement 
Previously, prophylactic regional lymph node dissections were common, resulting in quite a 
degree of morbidity in many patients, mainly due to wound complications and lymphedema. 
Randomized studies have demonstrated that prophylactic elective lymphadenectomies do not 
have any positive effect on patient survival96. In most countries, including Sweden, sentinel 
node biopsies are performed in melanomas >1.0 mm as well as in all ulcerated tumors or if 
mitotic rates are high61. A radioactive colloid as well as a blue color substance is injected at 
the site of the primary melanoma to identify the nearest draining lymph node(s) that is 
subsequently excised. If pathology examination detects melanoma cells in an excised lymph 
node, local lymph node dissections are performed. A large randomized study has shown that 
this method is efficient to prevent disease recurrences, but does not seem to effect disease 
survival97. The method is nevertheless an important tool for melanoma staging and could also 
take on an important role, if adjuvant therapies become implicated in standard melanoma 
treatment schemas.  
Today, there is no clear evidence of a benefit of studied systemic adjuvant regimens for high-
risk melanomas. High-dose interferon as well as immune checkpoint blockade with the 
CTLA4-inhibitor ipilimumab has shown some effectiveness but also considerable morbidity 
and mortality, and there are no predictive markers for therapy gain98,99. Currently there are 
ongoing studies on the adjuvant use of the PD-1 inhibitors pembrolizumab and nivolumab, 
and of the BRAF and MEK inhibitors vemurafenib, dabrafenib and trametinib33.  
Postoperative radiotherapy to metastatically involved regional lymph node stations has been 
shown to prevent local relapses but does not affect survival. In the Swedish national 
melanoma guidelines, postoperative radiotherapy is recommended after non-radical lymph 
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node dissections, if there is involvement of >3 lymph nodes, if size of lymph node metastasis 
is >3 cm or if there is periglandular involvement.  
1.6.3 Local management of melanoma metastasis 
Local recurrences (satellite tumors) in or adjacent to the previously operated primary 
melanoma or in transit metastasis should always be treated by radical surgery61,96. Metastatic 
survey with PET-CT, CT or MRI is recommended, as the risk for distant metastasis is 
substantial. If radical operation is not possible, postoperative radiation should be considered. 
In patients with frequent multiple local recurrences in a limb, but no signs of distant spread, 
isolated hyperthermic perfusion of the limb, with melaphalan has shown objective response 
in majority of cases and complete remissions in 60% of cases100. 
For limited, solitary distant metastasis there is some evidence of a survival benefit of radical 
surgery of such solitary metastases, e.g. in distant lymph nodes and subcutis and also in the 
liver, brain and other visceral organs. There is no evidence of a benefit of debulking non-
radical surgery of disseminated melanoma96. 
Brain metastases are common distant sites of melanoma. As mentioned previously, surgery is 
an option for solitary metastases. If the number of brain metastasis does not exceed 4-5 and 
lesions are small (≤2 cm), stereotactic gamma radiation is recommended. If there are more 
brain metastases, whole brain radiation can be considered. Glucocorticoid steroids, such as 
betamethason, should be used to improve symptoms of brain edema96. 
Palliative radiotherapy can also be considered for painful bone metastasis or for metastasis 
with threatening perforation and ulceration of the skin.  
1.6.4 Systemic therapies for stage IV melanoma 
Disseminated melanoma has until recent years been considered one of the more therapy-
resistant malignancies. Since dacarbazine was approved in the 1970s, no other chemotherapy 
agents have been approved for treatment of metastatic melanoma. Immunologic treatments 
involving interferons and interleukins have shown low response rates and considerable side 
effects, and are not recommended for melanoma treatment in many countries, including 
Sweden. While dacarbazine and its oral analog temozolamide, are still indicated in melanoma 
treatment, novel immunological and targeted therapies have entered the melanoma field with 
a vengeance. There are two different groups of new drugs that have been approved, the 
immune checkpoint inhibitors and inhibitors of the Ras-Raf-MEK-ERK pathway pathway 
(Figure 5 and 7). The first approved checkpoint inhibitor was ipilimumab that had shown a 
response rate of about 15%, but sometimes remarkable durable remissions24. The treatment 
has substantial, immune related, sometimes life-threatening side effects such as colitis, 
hepatitis, dermatitis and rarely also hypohysitis. The PD-1 blocking immune checkpoint 
inhibitors pembrolizumab and nivolumab were later shown to have higher response rates, 
improved progression-free and overall survival and milder side effects than Ipilimumab, and 
are currently considered the first line of immune-therapy in metastatic melanoma25,26. 
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Activating BRAF mutations at codon 600 (mainly V600E) are found in approximately 50% 
of melanomas, particularly in nodular and superficial spreading melanomas62,63. Vemurafenib 
was the first approved BRAF-inhibitory therapy for BRAF mutated melanoma. Objective, 
rapid and sometimes striking complete responses are seen in around 50% of metastatic 
melanoma cases, but therapy resistance and relapse usually develops after some months30. 
Although the therapy, which is in tablet form, is generally well tolerated it is sometimes 
complicated by quite peculiar side-effects such as photo-sensitivity and fast evolving benign 
and sometimes malignant keratinocytic skin lesions. Later, the BRAF inhibitor dabrafenib 
was approved. Dabrafenib has similar antitumor effect as vemurafenib, but is not associated 
with the same photo-sensitivity, but instead pyrexia is more frequent with this therapy32. 
Addition of the MEK-1 inhibitor trametinib has shown further improvements in survival, and 
less incidence of keratinocytic leasions, although pyrexia is more frequent31. Currently, there 
are several ongoing phase II-III studies on novel agents and treatment combinations which 
will hopefully lead to further improvements in the treatment of stage IV melanoma in the 
coming years33.  
1.7 BIOLOGY OF MELANOMA SUSCEPTIBILITY AND PROGRESSION 
1.7.1 UVR induced pigmentation and carcinogenesis 
The epidermis consists of two main cell types, the epidermally derived keratinocytes and the 
neural crest derived melanocytes101. Melanocytes are dendritic cells that are prominent in the 
skin, but are also found in other tissues, such as in mucous membranes, uveal tract and 
leptomeninges, in which primary melanocytic tumors also sometimes arise. The pigment 
melanin is produced in the melanocytes and is transferred to surrounding keratinocytes102. In 
what is known as an epidermal melanin unit, melanocytes are, through dendritic extensions, 
in direct contact with on average 10, but up to as many as 50 neighboring keratinocytes. 
There are two types of melanin pigment, the dark eumelanin that is abundant in dark skinned 
individuals, and the light-colored pheomelanin. Both eumelanin and pheomelanin are 
synthesized in the melanocyte from the precursor amino acid tyrosine. Both dark and light 
skinned people have equal amounts of pheomelanin, while eumelanin is absent or low in 
individuals with fair complexions and high in individuals with dark complexions102.  
The deep penetrating UV-A radiation, directly stimulates melanocytes to release melanin and 
also causes oxidation and darkening of existing melanin, leading to immediate tanning102 
(Figure 4). UV-B radiation causes inflammation, sunburn and apoptosis of keratinocytes, 
initiating a cascade of events leading to delayed tanning. The cellular damage of 
keratinocytes promotes production of α-Melanocyte stimulating hormone (α-MSH). α-MSH 
is a ligand of the Melanocortin-1 Receptor (MC1R). Activation of MC1R subsequently leads 
to activation of the transcription factor MITF with upregulation of tyrosinase (TYR), TYRP1 
and other enzymes leading to increased synthesis of melanin which is packed into 
melanosomes that are distributed to neighboring keratinocytes to protect the skin against 
further UVR damage. The signaling protein ASIP is an antagonist of the MC1R receptor that 
blocks the downstream production of eumelanin, increasing synthesis of pheomelanin.  
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Figure 4. Mechanisms of the cutaneous response to UVR.  
 
   Figure 5. RAS-RAF-MEK-ERK and PTEN pathways (A). p53 and RB pathways (B).  
Reprinted, with permission, from Miller et al. N Eng J Med 2006. 
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Variants in many of the genes involved in skin pigmentation, including MC1R, TYR, TYRP1 
and ASIP are associated with pigment features in individuals, and also with melanoma 
susceptibility, were some variant are associated with 1,1 – 5 fold risk increase of 
melanoma48,49 (Table 6).  
UVR (mainly UV-B, but also to some extent UV-A radiation) causes both directly and 
indirectly DNA damage and mutations. The indirect effect on DNA is mainly through the 
formation of free radicals that cause DNA mispairing and point mutations103. In contrast to 
eumelanin, pheomelanin is especially prone to photodegradation, generating free radicals that 
can cause mutations104. UVR is also directly absorbed in DNA causing typical UVR-
signature mutations (C→T, CC→TT)105. There are several DNA-repair proteins that 
recognize and repair DNA damage, but also in these genes there are polymorphisms and 
mutations that are associated with increased melanoma susceptibility, e.g. in the xeroderma 
pigmentosum (XP) genes XPG and XPF50. Individuals with certain polymorphisms in such 
genes only have low risk increases for melanoma (RR 1.1-1.7), while sufferers of xeroderma 
pigmentosum, an autosomal recessive disorder with biallelic mutations in nucleotide excision 
repair genes, including XP-A to XP-G, develop multiple skin lesions including melanomas 
and non-melanoma cancers106. XP cancers have multiple characteristic UV signature 
mutations, demonstrating the role of DNA-repair to hold back UV induced mutations.  
BRAF and NRAS mutations are often early, mutually exclusive events in the formation of 
melanocytic tumors and are frequently seen already in benign melanocytic nevi41,107,108. 
Although BRAF and NRAS mutations are mainly seen in melanomas arising on UVR-exposed 
areas, the mutations seen in these genes are mostly not typical UVR signature mutations. It 
has been suggested that in spite of the lacking classical UVR signature, these mutations could 
be secondary effects of UVR damage109. Other, later occurring mutations in genes such as 
tumor suppressors CDKN2A, PTEN and RAC1 are essential for the transformation to 
malignant melanoma, and mutations in these genes are often UV signature mutations110,111.  
1.7.2 RAS-RAF-MEK-ERK and PTEN-P13K-AKT pathways in melanoma 
The RAS-RAF-MEK-ERK (also known as MAPK pathway) and the PTEN-P13-AKT 
pathways are frequently activated in melanoma tumors (Figure 5a)41. Both pathways can be 
physiologically activated through receptor tyrosine kinases such as epidermal growth factor 
(EGFR) or c-Kit. The RAS proteins belong to a family of GTPases (including NRAS, HRAS 
and KRAS) located on the inside of the cell membrane. In melanoma, activating NRAS 
mutations (mainly at codon 61 and more rarely on codon 12-13) are found in approximately 
20% of tumors63,112. Activating mutations in NRAS can cause parallel activation of both the 
RAS-RAF-MEK-ERK and the PTEN-P13-AKT pathways. RAS proteins phosphorylate and 
activate proteins of the RAF family of serine/threonine kinases (including BRAF and CRAF). 
In melanoma, activating BRAF mutations (mainly at codon 600) are found in approximately 
50% of tumors63,112. Oncogenic activation through mutations in NRAS or BRAF triggers 
downstream signaling through MEK and ERK kinases with expression of Cyclin D1 which 
promotes cell proliferation41.  
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The PTEN-P13K-AKT pathway is regulated through PTEN, an inhibitor of the P13K kinase 
(Figure 5a)41. Inactivation of PTEN promotes cell survival by downregulating pro-apoptotic 
signaling through proteins AKT and BAD. The tumor suppressor gene PTEN is, after BRAF 
and NRAS, among the most frequently mutated genes in melanoma tumors113-115. PTEN 
mutations are hence believed to have an important role in the malignant dysregulation and 
malignant transformation of melanocytes. In a rare inherited condition, Cowden syndrome, 
germline mutations in PTEN are found116. Carriers of germline mutations in PTEN 
predominantly have increased risks of breast, thyroid and endometrial cancer, but also 
elevated risks of other cancers, including melanoma (Table 6). 
1.7.3 Pathways involving CDKN2A encoded tumor suppressor proteins p16 
and P14ARF 
The CDKN2A gene encodes two distinct proteins, p16 (INK4A) and p14ARF that are tumor 
suppressors and cell cycle inhibitors (Figure 5b)41,117. The gene has 4 exons, E1B, E1A, E2 
and E3. Separate first exons that are spliced into alternate reading frames of the second and 
third exons permit the expression of two different proteins, p16 and p14ARF, from the same 
genetic locus. Transcription can be initiated at either E1B or E1A which determines which 
gene will be expressed. The E1A containing transcript encodes the p16 protein which is 
structurally an ankyrin repeat protein, consisting of 4 separate ankyrin repeats that fold into 
the active protein that inhibits the cyclin dependent kinases CDK4 and CDK6. These two 
kinases drive the cell cycle by phosphorylating the retinoblastoma protein, pRB, releasing it 
from its inhibitory interaction with the E2F transcription factor, thereby allowing the 
expression of E2F-related genes and progression from G1 to S-phase. The cell cycle inhibitor 
p16 thus inhibits cell cycle progression while absence of p16 leads to unopposed CDK4 or 
CDK6 activity and increased cell cycle activity118,119. 
P14ARF, the other protein of the CDKN2A locus, transcribed in an alternate reading frame, 
works through yet another key cellular regulatory pathway. p14ARF sequesters the MDM2 
protein which is a negative inhibitor of tumor suppressor p53, also called, “guardian of the 
genome” due to its central role in protecting the organism from DNA damage and harmful 
mutations41,120. p53 either activates DNA repair and cell-cycle arrest or causes apoptosis. In 
the absence of p14-ARF, p53 levels are decreased resulting in uncontrolled proliferation.  
The CDKN2A gene is frequently mutated or deleted in melanoma tumors, leading to the 
disruption of p16 and/or p14ARF activity62. In addition, germline CDKN2A mutations are 
among the strongest known inherited genetic risk factors for cutaneous melanoma, being 
mutated in 5-25% of melanoma kindreds53,59. Germline mutations in CDK4, an oncogene, are 
also found in rare melanoma families121. Somatic mutations in TP53 and RB1 are rather 
common in melanoma tumors, but usually mutually exclusive with CDKN2A mutations. 
Germline mutations in TP53 (Li Fraumeni syndrome) and RB1 (Retinoblastoma) are cancer 
syndromes that are dominated by non-melanoma cancer types, although increased melanoma 
risk has been described in both syndromes122,123 (Table 6).  
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The transcription factor MITF has a central role in the regulatory functions of the melanocyte 
(Figure 4-5). MITF is regulated both through pigmentation pathways and Ras-Raf-MEK-
ERK signaling41,102. MITF regulates various cell processes through the transcription of 
proteins involved in pigmentation (TYR, TYRP1 and MC1R), proliferation and cell cycle 
regulation (p16, p21, CDK2) and apoptosis (BCL2)124. MITF is considered to be an oncogen 
in melanoma where the gene locus is infrequently duplicated125. A MITF gene variant, 
p.E318K has been shown to be associated with increased numbers of nevi and a moderate 
risk increase for melanoma. MITF is considered to be an intermediate melanoma risk gene 
(between the low-risk pigmentation genes and high-risk genes such as CDKN2A), with a 2-10 
fold risk increase in p.E318K carriers126-128 (Table 6). 
1.7.4 Telomere maintenance mechanisms in melanoma 
A telomere is a region of repetitive nucleotide sequences at each end of a chromatid, which 
protects the end of the chromosome from degradation or from fusion with neighboring 
chromosomes. Progressive shortening of telomeres with each cell division is a characteristic 
of normal aging cells, and may be hastened by exposure to harmful environmental exposures 
such as UVR or tobacco smoke128. A major determinant of cellular mortality is the telomere 
shortening that accompanies normal proliferation, so a key event in acquisition of cellular 
immortality is the up-regulation of a telomere length maintenance mechanism129,130. 
Telomeric DNA is bound by a protein complex called shelterin, which contains six proteins, 
TRF1, TRF2, TIN2, TERF2IP, ACD and POT1 (Figure 6)131. These proteins protect the 
telomeres and prevent telomere shortening. The enzyme telomerase lengthens telomeres by 
synthesizing new telomeric DNA, to compensate for replication-associated telomere 
shortening. Telomerase is a complex molecule with several subunits, including the reverse 
transcriptase TERT (Figure 6). Telomerase activity can be detected in human embryonic 
stem cells at levels which are sufficient to prevent telomere shortening. In contrast, somatic 
tissues have very low levels of telomerase and undergo telomere shortening throughout life. 
A majority of human cancers have detectable levels of telomerase, sufficient to prevent 
telomere shortening130. Mutations in the TERT gene promoter are found in many cancers, 
including melanoma, where it has been reported that UVR signature mutations are seen in 
33% of primary melanomas and in 85% of melanoma metastases132. In rare melanoma 
families, highly penetrant germline mutations have been found in the TERT promoter and 
also in shelterin complex genes POT1, ACD and TERF2IP133-135 (Table 6).  
1.7.5 Role of immune surveillance in melanoma 
One of the fundamental roles of the immune system is to distinguish self from non-self. In the 
late 1950s, the hypothesis of cancer immune surveillance emerged, suggesting that cancers 
can provoke an effective immunological reaction with regression of the tumor136. This is 
illustrated in patients that are immune suppressed that have increased risks for cancers, 
including melanoma137. Immune surveillance has been defined as having three key 
components: elimination (tumor eradication after antigen recognition), equilibrium 
(maintenance of tumor stability by immune control) and escape (tumor growth)138.  
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Figure 6. Components of telomere maintenance complexes. Reproduced, with permission, from 
Townsley et al. Blood 2014.  
 
 
Figure 7. Immune checkpoint regulation through CTLA-4 and PD-1.  
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There are several clinical examples of melanomas being immunogenic tumors139. An 
example of tumor elimination is metastatic melanoma with unknown primary tumor, 
sometimes with a patch of vitiligo at the postulated site of the original lesion that may 
represent immune recognition and elimination of the primary melanoma, supporting this 
hypothesis. Late recurrences of distant metastases (sometimes after decades) in patients with 
early-stage melanoma suggest prolonged periods of tumor equilibrium where tumor cells 
remain in a regional lymph node or at a distant site until a further event allows the tumor to 
escape. The mechanisms underlying increased immunogenicity of melanoma compared to 
many other tumors are unclear. One hypothesis relates to the high mutation rates seen within 
melanomas compared with other tumor types45. While cells with low mutational burden will 
display mostly normal cellular protein antigens on their MHC surface molecules without any 
immune activation, melanoma cells will display mutant proteins (tumor antigens), initiating 
an activation of the immune system140. A study on RNA expression profiles in melanoma 
metastases has shown inferior overall survival in tumors with a low expression of immune 
response genes74. Tumors often create an immunosuppressive microenvironment by 
mechanisms of immune suppression that prevent effective antitumor immunity. One 
regulatory pathway is through the CTLA-4 protein that after T-cell activation is upregulated 
on its plasma membrane and inhibits the T-cell function and suppresses the immune response 
(Figure 7). Another regulatory pathway involves the PD-L1 and PD-L2 ligands that are 
expressed on tumors and other cells and bind to PD-1 receptors on T-cells and inhibit their 
function. As described earlier, active melanoma therapies have emerged in the last years that 
inhibit immune checkpoints molecules CTLA-4 (ipilimumab) and PD-1 (pembrolizumab and 
nivolumab)140. 
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2 UVEAL MELANOMA 
2.1 INTRODUCTION 
William Norris, a pioneer in the study of melanoma, described in his 1857 study “Eight Cases 
of Melanosis with Pathological and Therapeutical remarks on that Disease” one case of 
ocular melanoma in a 15 year old who died from the disease4. Ocular melanomas are rare 
tumors that arise from melanocytes in the eye. Ocular melanomas are either conjunctival or 
uveal melanomas (see anatomy of the eye in Figure 8A). Conjunctival melanomas are 
extremely rare tumors (2-3 cases in Sweden yearly), that are more closely related to 
cutaneous and mucosal melanoma, but entirely distinct from uveal melanomas141. Uveal 
melanoma is as a disease entity very distinct from cutaneous melanoma, with entirely 
different etiology, epidemiology, biology, genetics and clinical aspects. Uveal melanoma, 
although rare is the most common form of intraocular cancer in adults, while retinoblastoma 
is the most common eye neoplasm in children. More than 90% of uveal melanomas involve 
the choroid, the remainder are confined to the iris and ciliary body. In posterior uveal 
melanoma, the choroid and/or ciliary body are affected, while in anterior uveal melanoma the 
iris is affected (Figure 8). 
2.2 EPIDEMIOLOGY AND RISK FACTORS 
The incidence of uveal melanoma is 2-8 cases per million inhabitants, per years in most 
western countries142. In Sweden there has been a stable incidence of 70-80 new cases 
yearly61. Contrary to cutaneous melanoma, there has been no incidence rise in uveal 
melanomas in the last decades. The incidence of uveal melanoma increases with age and 
peaks around 60 years, males and females are affected in equal numbers. Fair skinned and 
blue, grey or green eyed individuals have higher risks for the disease than brown eyed 
individuals142. Uveal melanomas can arise de-novo and also from uveal nevi. Uveal nevi are 
clusters of melanocytes seen in around 6% of the population where one in 5,000 undergo 
malignant transformation. Also congenital oculodermal melanocytosis and neurofibromatosis 
can predispose to uveal melanoma. Unlike cutaneous melanoma, the association between 
uveal melanoma and UVR is weak. Familial uveal melanoma cases exist, but are rare141,142.  
2.3 STAGING, CLASSIFICATION AND PROGNOSIS OF UVEAL MELANOMA 
Iris melanomas have the best prognosis, whereas melanomas of the ciliary body have the 
least favorable prognosis141,142. In the 2010 7th edition of the AJCC Cancer Staging Manual, 
the T categories for iris melanomas are different from the T categories for ciliary body and 
choroidal melanomas, while the N and M categories are the same for melanomas in all parts 
of the uvea143,144. For iris melanomas, a T1 tumor is only in the iris, a T2 tumor has grown 
into the ciliary body or choroid, a T3 tumor has grown into the sclera and a T4 tumor extends 
outside the eyeball. For posterior uveal melanoma, T is categorized based on tumor basal 
dimension and thickness into four increasing size classes (Figure 9A). Secondarily, T is 
classified according to specific anatomic extent regarding ciliary body involvement and 
extrascleral extension, which are both poor prognostic indicators. Tumor stages I-III spans all  
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Figure 8. Anatomy of the eye with the uvea consisting of the iris, ciliary body and choroid (A). Patient 
with an iris melanoma (B).  
 
 
Figure 9. AJCC tumor (T) classification of uveal melanoma (primary choroidal and ciliary body 
melanoma) defined by basal diameter and tumor thickness (A). AJCC anatomic stage of uveal 
melanoma defined by tumor, node, and metastasis values (B). Kaplan-Meier estimate of melanoma-
related death from posterior uveal melanoma in 7731 patients, based on the AJCC tumor staging (C). 
Reproduced, with permission, from Phoebe et al. Oman J Ophthalmol 2013  
 
Figure 10. GNAQ and GNA11 signaling pathways (A). Cellular functions of BAP1 (B). Reproduced, with 
permission, from Ladanyi et al. Clin. Cancer Res. 2012 and from Sullivan et al. Clin. Cancer Res. 2013. 
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T categories without local lymph node involvement or metastasis. Tumor stage IV is not 
subgrouped and includes all patients with local lymph node involvement or any distant 
metastases, illustrating the unconditional poor prognosis of uveal melanoma that has spread 
beyond the eye (Figure 9B). In stage I uveal melanoma the five year survival rate is high, 
97%. In stage II the five year survival is 90% and in stage III 75% (Figure 9C). A five year 
survival rate is not attained in stage IV uveal melanoma, since after one year survival rate is 
0%. Metastatic uveal melanoma invariably spreads to the liver. The liver is the most common 
site for uveal melanoma metastases, with 50% of patients having liver-only disease, and 90% 
of those with metastases elsewhere (commonly in lungs, bone, or skin) also having liver 
metastases142 
2.4 MOLECULAR BIOLOGY OF UVEAL MELANOMA  
On a molecular level, uveal melanomas are distinctive from cutaneous melanomas. Uveal 
melanomas are characterized by frequent (>80%), mutually exclusive mutations in guanine 
nucleotide-binding protein G(q) subunits alpha (GNAQ) and alpha-11 (GNA11), two closely 
related large GTPases of the Gaq family145. Guanine nucleotide-binding proteins are a family 
of heterotrimeric proteins that couple cell surface, 7-transmembrane domain receptors to 
intracellular signaling pathways. Oncogenic mutations in GNAQ and GNA11 render the 
GTPase constitutively active, triggering downstream signaling events leading to the 
activation of the MEK kinase (Figure 10A)146. This is similar to the consequence of 
mutations in the BRAF or NRAS oncogenes in cutaneous melanomas147. A frequent second 
event in uveal melanoma progression, are mutations or deletions of the BRCA1 associated 
protein (BAP1) gene locus148. The BAP1 gene maps to chromosome 3p21 and BAP1 
mutations in uveal melanomas are often accompanied by somatic complete or partial loss of 
chromosome 3. This is consistent with a two hit model with activation of GNAQ/GNA11 and 
loss of activity of a tumor suppressor gene BAP1147. Loss of heterozygozity in the BAP1 
locus has been associated with higher risks of metastatic uveal melanomas149. BAP1 is a 
deubiquitinase of histone H2A involved in chromatin remodeling. BAP1 forms multiprotein 
complexes with several chromatin-associated proteins, including BRCA1, BARD1 and 
HCF1150. The exact role of BAP1 has not been entirely clear, earlier reports suggested that 
the BAP1 tumor suppressor function was through its deubiquitinating activity upon BRCA1, 
but later studies have indicated that BAP1 is an independent tumor suppressor148. Further 
studies revealed its involvement in various biologic processes including chromatin dynamics, 
DNA damage response, cell cycle regulation and cell growth (Figure 10B)148,151,152. 
2.5 IMMUNE SURVEILANCE AND HOMING OF UVEAL MELANOMA CELLS 
The eye is a site of “immune privilege” where immune responses to antigens (including 
tumor antigens) are modulated to protect ocular tissues that, if damaged by inflammation, 
would compromise vision153. Anatomical constraints include the absence of afferent 
lymphatics within the eye and blood-ocular barriers that restrains traffic of immune cells to 
the eye and raise the threshold for priming of immune cells in secondary lymphoid organs. 
Immune cells that do enter the eye encounter significant biochemical barriers including 
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soluble immunosuppressive factors that limit T-cell functions. The immune suppressive 
mechanisms that maintain ocular ‘immune privilege’ are believed to be utilized by uveal 
melanomas to limit immune surveillance147. Uveal melanomas are characterized by tumor 
dormancy, with many patients experiencing distant metastatic recurrence, mostly to the liver, 
more than 5 years after treatment of the primary lesion147,154. The inclination of uveal 
melanoma to metastasize to the liver, has been attributed to hematogenous spread and homing 
to the liver through chemoattractant factors, increased adherence to liver endothelium of 
uveal melanoma cells and thriving in the microenvironment of the liver154,155. As local 
recurrences are uncommon it is believed that distant micrometastasis occurs before the 
treatment of the primary uveal melanoma. The molecular events involved in maintaining 
dormancy of micrometastasis are not known, but immunological control of metastatic cells, 
lack of angiogenesis within micrometastases and a low initial tumor cell proliferation has 
been suggested154. 
2.6 MANAGEMENT OF UVEAL MELANOMA 
2.6.1 Management of the primary tumor and follow-up 
Most uveal melanoma patients present with symptoms, including blurred vision, visual field 
loss, distorted vision, flashing lights, visible tumor, red eye and pain. 30-40% of patients are 
asymptomatic, their tumor being detected on routine ophthalmic examination by an 
optometrist or ophthalmologist142. Without timely treatment, uveal melanomas tend to make 
the eye blind, painful and unsightly as a result of retinal detachment, glaucoma and uveitis. 
The objectives of ocular treatment are to attempt to prevent metastatic disease and if possible 
to conserve the eye with as much useful vision as possible. The Collaborative Ocular 
melanoma study (COMS) from 1985 is the only evidence based study on the management of 
primary uveal melanomas156. Uveal melanomas were grouped into small (0-3mm thick), 
medium (3.1-8 mm thick) or large (>8 mm thick). The five-year survival in patients with 
small to medium-sized choroidal melanoma was equally high (~90%) in patients randomized 
to either radiotherapy or to enucleation. In Sweden eye preserving brachytherapy is standard 
for small to medium sized tumors, while enucleation is standard care in large tumors141. 
There is no evidence of a benefit of preoperative radiotherapy156. There is no consensus 
regarding the follow-up of uveal melanoma, which relates to the fact that metastatic disease is 
generally untreatable with no evidence of a benefit of early detection of metastasis. Since 
uvel melanomas are so rare, in Sweden the treatment of these tumors is centralized to one 
center, the St. Erik Eye Hospital in Stockholm were consensus is to offer biannual follow-up 
for 5 years after diagnosis, with abdominal ultrasound or CT scans141.  
2.6.2 Management of distant metastasis of uveal melanoma 
In patients with disseminated uveal melanoma, there are today no known therapies that effect 
survival outcomes141,142. Dacarbazine and its oral analog temozolamide, can give rare 
responses, but do not affect survival rates157. Among immune checkpoint inhibitors that are 
effective in metastatic cutaneous melanoma, ipilimumab has failed to show efficacy in uveal 
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melanomas, while occasional responses and clinical benefit has been reported with PD-1 
inhibitors158. BRAF or MEK inhibitors have not either been effective in the treatment of 
disseminated uveal melanoma159. As uveal melanoma patients often have isolated liver 
metastasis, several local liver treatment strategies have been applied. Patients with unilobar 
liver metastases have undergone liver resection, where a retrospective review found a median 
survival of 14 months, but 27 months in patients when surgery was radical160. In Gothenburg, 
Sweden, patients with liver metastasis only, receive isolated hyperthermic liver perfusion 
with melphalan. The phase II study of this method showed that patients had a promising 
median survival of 27 months and in 2013, the Scandium-study, a randomized phase 3 study 
was initiated and first interim analysis results from this study are expected in 2016161.  
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3 PRIOR KNOWLEDGE ON CANCER RISKS AND 
PROGNOSIS IN FAMILIAL MELANOMA KINDREDS 
3.1 CANCER RISKS IN CDKN2A MUTATED MELANOMA KINDREDS 
It is estimated that approximately 10% of all cases of cutaneous malignant melanoma occur 
in kindreds with hereditary predisposition for melanoma55,57. Among melanoma families 5-
25% carry a germline mutation of the CDKN2A gene162. In Swedish melanoma families, 
occurrence of CDKN2A mutations has been analyzed in studies from Southern Sweden and 
from Stockholm and were identified in 19% and 8% of the families, respectively163,164. In 
Sweden a single CDKN2A mutation, NM_000077.4: c.335_337dup, p.Arg112dup is the 
predominant mutation in melanoma families. The mutation inserts (duplicates) an arginine at 
codon 112 in one of the ankyrin repeats of p16-INK4A, disrupting its binding to CDK4/6. 
The mutation is located in CDKN2A exon 2 in a region that is also part of a second transcript 
with alternative reading frame, giving rise to a duplication of Ser-127 in p14ARF, still of 
unknown functional consequence 163,164. This mutation, which has only been detected in 
Sweden is a founder mutation estimated to have arisen in Sweden approximately 2,000 years 
ago165. Individuals with p.Arg112dup and several other CDKN2A mutations also have an 
increased risk of developing pancreatic carcinoma163,166-169. Several studies have reported an 
excess risk of other cancer types in CDKN2A mutated families, including gastrointestinal, 
breast, lung, neural system, gynecological, childhood, head and neck, non-melanoma skin 
cancers and uveal melanomas163,166,170-178, but these cancer risks are not as well established, 
nor as consistently observed as the increased risks of melanoma and pancreatic cancer. 
Higher risk of breast cancer has previously been reported in p.Arg112dup carriers from 
Southern Sweden163. In the study by Borg et al., nine p.Arg112dup families were analyzed, 
but it was later discovered that in one family with a high burden of breast cancer, family 
members had a germline mutation in the BRCA1 gene, in addition to the CDKN2A mutation, 
which may have contributed to the conclusion that there was a marked increase in breast 
cancer risk. In a study by de Snoo et al, specific cancer risks in melanoma families with the 
Dutch founder mutation (p16-Leiden) in CDKN2A were analyzed 166. In this study, the 221 
mutation carriers from 22 melanoma families had a significantly increased risk of cancers of 
the pancreas, respiratory tissues, lip, mouth and pharynx, digestive tissues female genital 
tissues and eye/brain. 
In CDKN2A carriers, melanoma risk has been positively associated with sun exposure58, but 
apart from this there have been no studies so far investigating the association of exposures to 
other carcinogens, such as those in tobacco smoke, on cancer risk in CDKN2A mutation 
carriers from melanoma prone families. In three separate case reports of CDKN2A mutation 
carriers that were smokers and/or alcohol consumers, cancers of the tongue, oral cavity, 
pharynx and lung have been reported171,176,178. Another study showed that among subjects 
that ever smoked, the risk of pancreatic cancer was higher in CDKN2A mutation carriers 
compared with non-carriers, but among non-smokers the risk for pancreatic cancer was not 
significantly different in carriers and non-carriers. Although interesting, this study was 
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limited by a low number of confirmed carriers (n=9), which were all carriers of different 
CDKN2A mutations 179. 
3.2 CANCER RISKS IN CDKN2A WILD TYPE MELANOMA KINDREDS 
High-risk melanoma associated mutations in genes other than CDKN2A have yet only been 
identified in a small number of families, in the majority of melanoma families, the cause for 
heredity still remains unsolved. In a few melanoma families, germline mutations in CDK4, 
POT1, ACD, TERF2IP and TERT genes have been found132-135,180. Although several other 
cancers have been observed in some of the families carrying these mutations, the numbers of 
known carriers are too still too few for statistical risk estimation. In families with the MITF 
E318K variant, increased risks for melanoma and renal cell carcinoma have been 
observed126,127. Also, in individuals with germline mutations in PTEN, RB1, TP53, BRCA1 
and BRCA2, increased risks of melanoma have been described, although the cancer 
phenotypes are dominated by other tumor types (Table 6, p. 18)116,122,181,182. 
While germline mutations in high penetrance cancer predisposing genes are very rare in the 
normal population, single nucleotide polymorphisms (SNPs) in low penetrance genes like 
MC1R, ASIP, TYR and TYRP are relatively common49. These low-risk melanoma genes are 
involved in cellular pigmentation pathways and population frequencies differ between 
countries and ethnic groups. Variants in low-risk melanoma genes have been associated with 
sporadic and familial melanoma, as well as with basal cell and squamous cell skin cancers, 
but no association has been made with increased risks of non-skin cancers48,49. In a study by 
Höiom et al., on sporadic and familial melanomas in Stockholm, carrier frequencies of 
multiple MC1R variants were 21%, 30% and 40% in controls, sporadic and familial 
melanoma, respectively, indicating a gene dose effect48. 
Previously, there have been no studies investigating the cancer risk in CDKN2A wild type 
(wt) melanoma families. While extensive molecular research is needed to identify new 
mutations or genetic variants associated with hereditary melanoma, clinically orientated 
studies in cohorts of families negative for mutations in known melanoma high-risk genes are 
also needed for a better understanding of this group.  
3.3 PROGNOSIS IN MELANOMA FAMILIES DEPENDING ON CDKN2A 
MUTATION STATUS 
Several studies have compared patient and tumor specific factors among germline CDKN2A 
mutation carriers to non-carriers. In summary, the only consistent finding has been that 
CDKN2A mutation carriers are younger at melanoma diagnosis. Findings on differences in 
tumor specific features such as body site, ulceration, regression, presence of oncogenic BRAF 
or NRAS mutations have been non-significant or discordant (Table 7)183-187. In melanomas 
from CDKN2A mutated individuals, there is a vague trend towards an increase in superficial 
spreading melanomas and lower Clark levels and Breslow thicknesses. Notably, in the 
reviewed studies, either it is not specified whether the first melanoma diagnosed or 
subsequent melanomas are used for comparative analysis or both first and later melanomas  
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are both used in the studies. This is of importance since multiple melanomas are very 
common among familial melanoma cases and the first melanoma is commonly the thickest, 
since after the first melanoma awareness increases, resulting in subsequent melanomas being 
thinner and less invasive54. Also, in most of the studies, sporadic melanoma cases have been 
used as control groups and these have not received the same dermatologic follow-up as 
members of melanoma families that indeed has the goal to identify melanomas at earlier 
stages. The presumption that melanomas of CDKN2A mutation carriers have more favorable 
prognostic features has lead to speculations that mutation carriers might have similar or even 
more beneficial outcomes from their melanomas, but research addressing this specific 
question have until now been entirely lacking. 
 
 
3.4 GERMLINE MUTATIONS IN UVEAL MELANOMA FAMILIES 
Familial predisposition to uveal melanoma is rare and has been suggested to account for less 
than 1% of all cases188. However, families have been described with uveal melanoma cases 
along with several other malignancies, indicating that uveal melanoma may be a part of 
hereditary conditions with predisposition to other types of cancer in some kindreds. The 
proportion of patients with uveal melanoma with inherited susceptibility might therefore 
previously have been underestimated189. The existence of an association between uveal 
melanoma, breast cancer, and ovarian cancer has been previously proposed190. As described 
earlier, mutations and deletions in the BAP1 tumor suppressor gene is a common somatic 
event in uveal melanomas and associated with worse prognosis147-149. It has been 
demonstrated that germline alterations in the BAP1 gene underlies inherited predisposition of 
cancer related syndromes characterized predominantly by mesothelioma or melanocytic 
tumors together with isolated cases of uveal melanoma and other tumors191-193. It has also 
Table 7. Summary of previous studies on patient and tumor specific factors in CDKN2A  mutated 
familial melanoma cases compared to controls.
Zebary Staaf van der Rhee Måsbäck Sargen
et al. 2013 et al. 2014 et al. 2010 et al. 2002 et al. 2015
n=89 n=43 n=182 n=26 n=123 Summary
Control group Spor/wt fam Sporadic Sporadic Sporadic Spor/wt fam 3/5 studies only have sporadic mel controls
Age at diagnosis ↓ (NS) ↓ (S) ↓ (S) ↓ (S) ND CDKN2A mut significantly younger
Gender ↔ ↔ ↔ ↔ ND No significant findings
Site ↔ ↑Extr, HN (NS) ↔ ↑ HN (NS) ND No significant findings
Histology type ↓SSM (NS) ↑SSM (NS) ↑SSM (S) ↓SSM (NS) ↑SSM (NS) Discordant findings, trend towards SSM in CDKN2 Amut
Breslow ↓ (NS) ↓ (NS) ND ↓ (NS) ND No sign. findings, trend towards ↓Breslow in CDKN2A mut
Clark ↓ (NS) ↓ (S) ↓ (NS) ↓ (S) ND Trend towards ↓Clark in CDKN2A mut
Ulceration ↓ (NS) ND ND ↑ (NS) ↔ No significant findings
Regression ND ND ND ↔ ↓ (NS) No significant findings
BRAF mutations ↑ (NS) ↑ (NS) ND ND ND No sign. findings, trend towards ↑BRAF in CDKN2A mut
NRAS  mutations ↓ (NS) ↓ (NS) ND ND ND No sign. findings, trend towards ↓NRAS in CDKN2A mut
Mult. Primary mel. ND ND ↑ (S) ND ND ND in 4/5 studies. Sign increased in one study
First or secondary Both ND Both ND ND ND in 3/5 studies. Both first and secondary mel in 2/5
mel in study
S: Significant, HN: Head neck area Spor: Sporadic controls
NS: Not significant Extr: Extremities Wt fam: Familial melanoma controls with wild type CDKN2A mutation status
ND: No data Mel: Melanoma CDKN2Amut: Familial melanoma cases with mutation in CDKN2A 
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been reported that BAP1 germline mutations were found in families with uveal melanoma in 
combination with cutaneous melanoma and/or other cancer types and rarely in families 
without uveal melanomas194,195. In a study by Jönsson et al. linkage-based evidence for the 
presence of a susceptibility gene was detected on 9q21 in three large Danish families with 
predisposition of both cutaneous and uveal melanomas. So far, no candidate gene has been 
identified; however, this substantiates the existence of several separate susceptibility genes 
for uveal melanoma196. 
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4 SWEDISH HEALTH CARE SYSTEM AND REGISTRIES: 
TOPICS RELEVANT FOR THE THESIS 
4.1 SWEDISH HEALTH CARE SYSTEM 
As in the other Nordic countries, Swedish health care system is mainly government-funded 
and financed primarily through taxes. The responsibility for health and medical care in 
Sweden is shared by the central government, the 20 health care regions (landsting) and the 
290 municipalities (kommuner)197. All Swedish residents have equal access to the public 
health care system. There is a limit on yearly health related costs paid by the patient, health-
care fees over 1,111 SEK (€120) and prescription medicine costs over 2,200 (€240) are paid 
by the government for the rest of the year. Primary health and emergency care is available 
directly, while a referral from a primary health care physician or another specialist is required 
for specialist appointments within the public health sector. In most specialty fields, the 
issuing of clinical guidelines as well as registration of patients (for quality assessments and 
research) is organized on a regional and national level. Management on different aspects of 
cancer prevention and care is coordinated by six Regional Cancer Centers (RCC) that work 
both individually and cooperatively.  
4.2 FOLLOW-UP OF MELANOMA FAMILIES IN SWEDEN 
The Swedish Melanoma Study group (SMSG), formed in 1977, is a multidisciplinary 
network of melanoma health care professionals and scientists from all health care regions198. 
The aim of the SMSG is to ensure a high quality and equality of melanoma health-care in 
Sweden. SMSG formulates national clinical guidelines on the prevention and management of 
melanoma, coordinates academic melanoma studies and registration of melanoma patients in 
the National Melanoma Quality Registry. In 1985, SMSG initiated a working group on 
familial melanoma. At the time, familial melanoma was regard as a “dysplastic nevus 
syndrome” (DNS) and the group was called the DNS group. In 2014 the name of this group 
was changed to the Swedish Network on Familial Melanoma (SweFaM), reflecting the 
current knowledge, that familial melanoma is not necessarily associated with dysplastic nevi. 
The task of the group was to, on a national level, identify and register melanoma families, 
formulate clinical guidelines, organize primary and secondary preventive measures and to be 
a platform for research. In 1987 the first clinical guidelines were issued and enrollment of 
melanoma family members in a preventive program started. The initial criteria for 
participation were cutaneous melanomas (invasive or in situ) in at least two blood relatives 
(first-, second- or third-degree relatives) as well as clinical dysplastic nevi in two or more 
relatives (“D-2 kindreds). Familial melanoma kindreds were identified through questioning of 
newly diagnosed melanoma patients regarding family history of melanoma. Melanomas in 
relatives were verified by pathology reports and/or clinical records. A pedigree was 
established and blood relatives, contacted by the proband, were invited to participate in the 
program. At the initial visit, participants received written and oral information regarding 
protection from damaging sunlight and skin self-examination. Skin examination and photo 
documentations were performed. Individuals who were diagnosed with melanoma and 
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unaffected individuals with dysplastic nevi were followed-up at 6-month intervals. Since 
mid-1990s, melanoma family members have also been invited, for the purpose of study, to 
undergo CDKN2A mutation testing. This program was reviewed and evaluated in a 2007 
paper by Hansson et al54. From 280 melanoma families, 2,080 family members had been 
enrolled, 614 with melanoma and 866 relatives with dysplastic nevi only and 600 relatives 
without melanoma or dysplastic nevi. Between 1987-2001, 26 invasive and 15 in situ 
melanomas, as well as 766 histopathologically dysplastic nevi, were excised. The majority of 
melanomas (66%) were identified in individuals previously diagnosed with melanoma. In 
addition all melanomas, except one, were diagnosed in families with at least two first-degree 
relatives with melanoma. As a result of this study and also of other studies with similar 
findings, the definition of melanoma has become more stringently focused on the numbers of 
melanomas and degree of relation between the melanoma cases in families rather than on 
dysplastic nevi. The more melanomas in a family and the closer the blood-relations is 
between affected individuals, the higher is the risk of new melanomas evolving and the 
higher is the proportion of families that carry high-risk melanoma associated mutations such 
as in the CDKN2A gene (Table 5, p. 9)53,59. 
4.3 REGISTRIES EMPLOYED IN THE THESIS 
4.3.1 Personal identification number and the Swedish Population Registry 
The Swedish 10 digit personal identity number (personnummer) was introduced in 1947 and 
was first of its kind covering the total resident population of a country. Numbers are issued by 
the Swedish Tax Agency (Skatteverket) as part of population registration199 The individually 
unique personal identity number is assigned to each Swedish resident at birth or from the time 
of permanent residency. The first 8 digit encode information on the date of birth (year-month-
day) and the last 4 digits are based on algorithms that ensures a unique number, including 
information on gender. The personal identity number is used by authorities, employers, 
banks, health care, registries etc. The personal identity number is crucial to cross link national 
register data for the purpose of study. The Population Registry, kept by the Tax Agency, is 
the civil registration of vital events (e.g. births, deaths, and marriages). Until 1991, the 
Population Registry was under the church, and although not complete, goes back many 
centuries. In Papers I-III, the Swedish personal identity number was used for registry linkages 
and the Population Registry was used to attain census data on all subjects, and in Papers I-II 
to identify control subjects.  
4.3.2 The Swedish Multi-generation Registry 
Swedish Multi-generation Registry contains connections between all individuals born after 
1931 (index persons) and their biological parents that have been registered in Sweden after 
1960200. The Multi-generation Registry is held by Statistics Sweden (Statistiska Centralbyrån) 
that retrieves information on the biological mother and father of index persons from the 
Population Registry system, which identifies the relationship between mother and child and 
between father and child. There are about 10 million index persons in the registry. If an index 
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person’s parent was dead or emigrated before 1961, then data on that parent is missing from 
the registry. For index persons who were adopted, there is also information on their adoptive 
parents. The Swedish Multi-generation Registry was used in Papers I-III.  
4.3.3 The Swedish Cancer Registry 
The Swedish Cancer Registry was founded in 1958 and covers the whole population. The 
registry is held by the Swedish National Board of Health and Welfare. Reporting to this 
registry is by law, compulsory for clinicians and pathologists or cytologists diagnosing a 
cancer. Approximately 60,000 malignant cases of cancer are now registered every year in 
Sweden. In the registry, there is patient specific information such as personal identity 
number, age, sex and date of death and tumor specific data such as site of tumor, histological 
type, and stage. Site of the tumor is coded according to ICD, but there have been different 
versions used, depending on the time span each version was in use. For unison registration, 
all cancers are still coded by ICD-7 codes, while tumors diagnosed from 1987 are also coded 
by ICD-9 codes. Cancers diagnosed after 1993 are also coded by International Classification 
of Diseases for Oncology codes (ICD-O). Since 1993 by ICD-O-2 and since 2005 by ICD-O-
3. Histological types have since 1993 been coded according to ICD-O/2 and since 2005, ICD-
O/3. From 1958 and onward, the codes are also available as the old histology code 
WHO/HS/CANC/24.1. For most tumors, stage has been collected since 2004 according to the 
AJCC TNM classification system. Completeness of the registry has been estimated to 97%201. 
The Swedish Cancer Registry was used in Papers I-III. It should be noted that the registry 
does not systematically record basal cell carcinomas of the skin, therefore these tumors are 
not included in the present studies.  
4.3.4 The Stockholm-Gotland Regional Melanoma Registry 
The Regional Cancer Center (RCC) in Stockholm-Gotland was founded in 1976. One of its 
tasks was to register cancer patients; data has been collected on melanoma patients in the 
Stockholm-Gotland Regional Melanoma Registry since 1976. Data is registered on patient 
and tumor characteristics, including TNM stage, treatments and follow-up. Since 2003 data is 
passed on to the Swedish Melanoma Registry that collects data from all regions for purpose 
of quality control. The Stockholm-Gotland Regional Melanoma Registry was used in Paper 
III.  
4.3.5 The Swedish Cause of Death Registry 
For every death in Sweden, a physician issues, within 24h a death certificate to the Tax 
Agency and, within 3 weeks a cause of death certificate to the National Board of Health and 
Welfare (Socialstyrelsen)199,202. The Swedish Cause of Death Registry, held by the National 
Board of Health and Welfare has data from 1961, the year when the registry started. The 
physician reports the underlying cause (e.g melanoma) that subsequently leads to death. The 
underlying causes of death is coded in the registry by ICD codes, but there have been 
different versions used, depending on the time span each version was in use. Registration is 
almost complete, with <1% missing certificates yearly. The quality of the data depends on the 
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thoroughness and accuracy of the physician report, which can vary. In a study of reporting to 
the registry in 1995, there was a discrepancy in 23% of cases between hospital discharge note 
and the cause of death certificate203. The highest discrepancy was seen in elderly with 
multiple morbidities, while the lowest discrepancy was seen in cancer patients (8%). The 
Swedish Cause of Death Registry was used in Paper III.  
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5 AIMS OF THE THESIS 
The main aim of this thesis is to gain more knowledge on the effect of mutation status in 
melanoma-associated genes on cancer risks and prognosis in familial melanoma kindreds.  
 
More specifically: 
I. To study the risk of melanoma and non-melanoma cancers in germline CDKN2A 
mutation carriers identified in Swedish melanoma families. Swedish Registries, 
including the Multi-generation Registry and the Cancer Registry are used for this 
purpose. 
 
 
II. Also, with the aid of Swedish registries, to estimate the risk of melanoma and non-
melanoma cancers in CDKN2A mutation-negative familial melanoma kindreds.  
 
 
III. To compare survival from all causes, from melanoma and from non-melanoma 
cancers in CDKN2A mutation-positive or -negative familial melanoma kindreds. 
 
 
IV. To identify germline gene mutations associated with hereditary uveal melanoma 
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6 MATERIALS AND METHODS 
6.1 STUDY DESIGN 
Papers I-III are cohort studies of cancer risks and prognosis in familial melanoma kindreds 
and controls. Although these studies were planned and carried out in 2012-2015, the register 
data used on cancer diagnoses and deaths is prospectively registered from the date when the 
families were identified. Paper IV is a case study with a family-based association analysis. 
The main feature of this type of association analysis is that controls are family-based rather 
than population-based. 
6.2 ACCRUAL OF CASES  
6.2.1 Identification of familial cutaneous melanoma kindreds: Papers I-III 
As described earlier (paragraph 4.2) Swedish melanoma families have since 1987 
systematically been enrolled in a nationwide preventive program. Since 1995, CDKN2A 
mutation analysis has been offered to family members, for the purpose of study. Mutation 
analysis has mainly been carried out at the Lund University and at Karolinska Institutet in 
Stockholm. Totally, 861 family members from 321 melanoma families that have undergone 
CDKN2A mutation testing were included in the register studies. Informed consent was 
obtained before family members underwent mutation analysis and the study was approved by 
Research Ethical Review Boards in Lund and Stockholm. 
6.2.2 Identification of familial uveal melanoma kindreds: Paper IV 
At the Oncology clinic at Karolinska University hospital in Stockholm a rare uveal melanoma 
family was identified in 2010. The proband, a female, had at age 16 years been diagnosed 
with a choroidal melanoma, with tumor stage T4N0M0. The patient underwent enucleation of 
the right eye but six months later she was diagnosed with multiple liver metastasis and later 
bone metastasis and subsequently died from the disease. When the patient and her parents 
were asked about other cancers in the family, it become known that the patient had two 
relatives with uveal melanoma, her paternal grandfather and his brother had been treated for 
the disease at 39 and 44 years, respectively, and both later died from disseminated disease. 
The patient’s father, at the time in his early forties, had no cancer diagnosis. No unusual 
cancer predisposition was seen on the patient’s maternal side. Due to the three cases of uveal 
melanoma in a family, all diagnosed at earlier ages than is normally seen, in particular in the 
proband, this was considered a hereditary case of uveal melanoma. A pedigree was 
established using information from the proband’s parents and from medical records. Informed 
consent from living family members was obtained, and the study was approved by the 
Research Ethics Board of Karolinska Institutet. Blood samples for extraction of germline 
DNA from the proband, her parents and a healthy younger sister for exome sequencing. From 
the extended pedigree, six family members donated a blood sample for follow-up genetic 
analysis. One of them was a dizygotic twin brother of the proband’s paternal grandfather who 
was diagnosed with prostate cancer at 67 years. Paraffin-embedded archival material from 
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primary uveal tumor surgical specimens were collected from the affected proband, her 
grandfather, and his brother.  
Additional screening of candidate predisposing genes was done in three patients with uveal 
melanoma from three other families using DNA from archival tumor material from all the 
individuals and germline DNA from blood for two of the three individuals. The investigated 
families all had two first- or second-degree relatives with uveal melanoma, and one of the 
families also had one case of cutaneous melanoma and one case of mesothelioma. 
6.3 MUTATION AND GENE VARIANT ANALYSES 
6.3.1 Genotyping of the CDKN2A gene: Papers I-III  
From familial melanoma kindreds, 8 ml of venous blood were drawn and peripheral blood 
mononuclear cells were isolated, from which DNA was extracted with FlexiGene DNA kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Polymerase chain 
reaction (PCR) was performed on exons 1α, 1β, 2 and 3 of CDKN2A to give PCR fragments 
of 340 bp, 678 bp, 576 bp and 319 bp for exons 1α, 1β, 2 and 3, respectively. PCR conditions 
were: initial denaturation and DNA polymerase activation at 95° C for 6 min followed by 40 
cycles of 95° C for 10 sec, 61°C, 59°C, 60°C or 62°C (for exons 1α, 2 and 3, respectively) for 
20 sec and 72°C for 30 sec. The cycling was followed by 5 min. incubation at 72°C then soak 
at 4°C. The PCRs consisted of 1X PCR buffer, 0.2 mM dNTPs, 1.5 mM MgCl2, 1 U of 
Platinum Taq polymerase (all reagents from Invitrogen, Carlsbad, CA), 1 M of betaine (exons 
1α and 2) or 5% of DMSO (exon 3) (both Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany), or no additives with 20 pmoles of each primer (Eurofins-MWG GmbH, 
Ebersberg, Germany) and 50 ng of genomic DNA in a total volume of 20 µl. Exon 1β PCR 
was run using the PCRx Enhancer System™ (Invitrogen, Carlsbad, CA) at final PCRx 
Enhancer solution concentration of 1X, in 1X PCRx Amplification buffer, 0.2 mM dNTPs, 
1.5 mM MgSO4, 30 pmoles of each primer and 3 U of Platinum Taq polymerase (all reagents 
Invitrogen, Carlsbad, CA) with PCR conditions as above except with an annealing 
temperature at 56°C. 3 µl of each PCR product was run on a 1.6 % agarose gel to confirm 
PCR specificity. Ten µl of the PCR product was purified using 2 U of exonuclease I and 1 U 
of FastAP alkaline phosphatase (both Thermo Fisher Scientific, Gothenburg, Sweden). The 
purification conditions were 50 min at 37°C followed by 20 min at 80°C then soak at 4°C. 0.5 
to1.0 µl of the purified PCR corresponding to approximately 25 to 50 ng of PCR product was 
used in a sequencing reaction utilizing Applied Biosystems BigDye Terminator Cycle 
Sequencing Kit version 1.1 according to a 1:4 protocol with 1 µl of BigDye Terminator™ in 
a final 0.75X BigDye Terminator sequencing buffer (reagents Applied Biosystems, Foster 
City, CA) and 4 pmole of each primer (Eurofins-MWG GmbH, Ebersberg, Germany) in total 
volume of 10 µl. The sequencing reactions were analyzed in ABI Prism® 3700 genetic 
analyzer (Applied Biosystems, Foster City, CA) All PCR products were sequenced bi-
directionally, with analyses of electropherograms using Mutation Surveyor v.3.97 software 
(Softgenetics LLC, State College, PA). 
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6.3.2 Genotyping of the MC1R gene (Paper III) 
Using direct sequencing the whole coding region and 5′proximal part of the MC1R gene 
starting at position-325 was analyzed in DNA from 100 subjects48. Ten variants were found 
to be present in DNA from sporadic melanoma patients and control individuals. These 
variants and an additional 11 MC1R variants chosen from the literature were then screened 
for using DNA from control subjects and patients. The literature based MC1R variants were 
selected to have an elevated allele frequency in populations of European ancestry. DNA from 
sporadic and familial melanoma cases and control subjects was genotyped for the 21 
identified MC1R variants using Protease mediated Allele-Specific Extension (PrASE). 
Shortly, this is a multiplex, chip-based SNP genotyping method utilizing allele-specific 
oligonucleotides with unique (for the specific allele), non-cross hybridizing 5′-ends. These 
oligonucleotides are annealed to a single-strand immobilized PCR product and elongated 
with fluorescence labelled nucleotides. The time for elongation of an oligonucleotide with 
matching 3′-end in relation to an oligonucleotide with non-matching 3′-end gives the allele 
specificity: elongation of the non-matching oligonucleotide is interrupted by protease 
degradation of the DNA polymerase. The labelled oligonucleotides are then hybridized to a 
chip with immobilized complementary anti-tag oligonucleotides to give signal. 
6.3.3 Whole-Exome sequencing and Sanger sequencing of the BAP1 gene: 
Paper IV 
From familial uveal melanoma kindreds, 8 ml of venous blood and DNA extracted. 10 μg of 
genomic DNA was extracted and paired-end libraries were created according to standard 
protocols (Illumina, San Diego, CA). Whole-exome enrichment was performed using the 
TrueSeq Exome Enrichment Kit (Illumina). Enriched libraries were sequenced using Illumina 
HiSeq 2000 generating 2 x 100 bp reads. Before mapping, quality control was performed by 
30-trimming of reads, removing bases with a Phred score encoded by ‘‘B,’’ which is an 
Illumina quality-control indicator, indicating that the read end should not be used in further 
analyses. If a read after trimming was less than 40 bases long it was removed. Furthermore, 
reads having five or more bases with a Phred score of 10 or lower or 10 or more bases with a 
Phred score of 20 or lower were discarded. In addition, reads with four or more uncalled 
bases were also discarded. Overall quality after quality-control filtering was verified by 
manual inspection of FastQC reports. Reads were mapped using Mosaik to the hg19 
reference genome allowing a maximum of four mismatches, and thereafter PCR duplicates 
were removed (MosaikDupSnoop). Variants [single-nucleotide variants (SNVs) and indels] 
were mapped using SAMtools with default parameters and thereafter prefiltered with vcfutils 
using default parameters apart from the maximum read-depth parameter, which was set to 
maximum three times the average consensus coding DNA sequence (CCDS) coverage, as to 
avoid regions with abnormal mapping behavior. Identified variants were annotated using 
Annovar and custom Perl and R scripts.To retrieve a subset of candidates, variants were 
filtered based on the annotations. Different sets of filters were used, generating candidate lists 
of variants: (1) nonsynonymous SNVs (2) frameshift indels, and (3) variants affecting 
splicing and miRNA/miRNA targets. Gene variants were also filtered based on their putative 
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effect (on the protein, frameshift, splicing, etc) and if they were in conserved regions. 
Variants were excluded if they were located in segmental duplicated regions and if they had a 
minor allele frequency more than 1% (1000 Genome Project dataset, release November 
2010). Finally, only variants shared between the proband and her father but not present in the 
mother were included. 
Germline DNA was extracted from peripheral blood using FlexiGeneVR DNA kit 
(QiagenVR, Hilden, Germany). Tumor DNA was extracted from archival material using 
QIAampVR DNA FFPE Tissue kit (Qiagen). Validation of the mutation identified by exome 
sequencing was performed bybidirectional sequencing of a fragment obtained by PCR. From 
germline DNA, a fragment covering exons 1–3 of BAP1 was amplified and sequenced using 
primers designed for targeted resequencing provided by the NCBI Probe database. Screening 
of all BAP1 exons was done using resequencing amplicon probe sets from NCBI Probe. From 
paraffin-embedded archival tumor DNA, a shorter fragment of 150 bp covering the position 
c.75 in exon 3 of BAP1 was amplified. Two informative microsatellite markers (D3S1578 
and D3S3026) flanking the BAP1 gene locus were used for genotyping. 
6.4 REGISTER LINKAGES AND FOLLOW-UP (PAPERS I-III) 
The national 10-digit personal identity number of each CDKN2A tested familial melanoma 
kindred was linked with the Swedish Multi-generation Registry. This allowed identification 
of familial melanoma kindreds’ first-degree relatives (parents, siblings and children) and 
second-degree relatives (grandparents, uncles/aunts, nieces/nephews, half-siblings and 
grandchildren). Age and sex matched controls were identified from the Swedish Population 
Registry. The personal identity numbers of identified family members and controls were 
linked with the Swedish Cancer Registry to obtain data on all registered cancers (types, stages 
and dates) and with the Cause of Death Registry to obtain data on all deaths (causes and 
dates). In Paper III, sporadic melanoma cases, matched for age, sex, tumor thickness and year 
of diagnosis in familial melanoma cases, were obtained from the Regional Melanoma 
Registry of the Stockholm-Gotland health care region.  
In Papers I-II, follow-up started the date the first blood sample was taken for CDKN2A 
analysis in each family (same date in family members and corresponding controls) and ended 
at the date of death, emigration or census date of December 31st, 2011. In Paper III, follow-
up started at the date when the first invasive melanoma was diagnosed in each case and ended 
at the date of death, emigration or census date of December 31st 2011. 
6.5 STATISTICAL ANALYSES 
6.5.1 Basic statistical analyses (Paper I-III) 
In the CDKN2A genotyped familial melanoma kindreds, median ages and ranges were 
calculated (Papers I-III). Relative risks (RR) for cancers were calculated from incidence rates 
(number of cancers/person years) (Papers I-II). To estimate age specific cumulative cancer 
incidence in CDKN2A mutation carriers, the incidence of cancer was analyzed in 10 year 
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intervals from 0-80 years of age (number of cancers/persons alive in each interval) (Paper I). 
Odds ratio (OR) was calculated for smoking status (ever/never) and having been diagnosed 
with cancers in pancreas, respiratory and upper digestive tissues (yes/no) (Paper I) and also in 
calculations on allele frequencies of red hair color (RHC) variants in the MC1R gene in 
familial melanoma kindreds and controls (Paper II). Two sided 95% confidence intervals 
(95% CI) were calculated for all relative risks (RR and OR). In Paper III, student T-test was 
used to calculate p-values for continuous variables (age) and chi-square test to calculate p-
values of categorical variables (sex; female/male, multiple primary melanoma; yes/no, etc.). 
A p-value <0.05 was considered significant. 
6.5.2 Survival analysis (Paper III) 
Survival from all causes, from melanoma and from non-melanoma cancer was studied. For 
overall survival, all deaths were considered as events. For melanoma-specific survival, only 
deaths from melanoma were counted as events, deaths from other causes were labeled as 
censored and follow-up ended on the date of death. In the same way, for non-melanoma 
cancer-specific survival, only deaths from non-melanoma cancers were counted as events, 
deaths from other causes were labeled as censored and follow-up ended on the date of death. 
For survival analysis, the Kaplan-Meier method was used along with Log-rank test to 
estimate the hazard function of groups at each observed event time. The Cox proportional 
hazards regression model was used to analyze survival outcome by producing hazard ratios 
(HR) unadjusted or adjusted for age, sex and tumor thickness. Statistical analyses were done 
in StatSoft Statistica 10. 
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7 RESULTS 
7.1 RESULTS FROM PAPER I 
“High Risk of Tobacco-Related Cancers in CDKN2A Mutation-Positive 
Melanoma Families" 
In carriers of the Swedish founder mutation in CDKN2A (p.Arg112dup) (n=120), the 
prospective relative risks (RRs) of all non-melanoma cancers was 5.0 (95% CI 3.7-7.3) 
compared to controls and 4.8 (95% CI 2.4-10.1) compared to their related non-carriers. 
Compared to controls, the RR of melanoma was 64.8 (95% CI 36.9-117.9), of pancreatic 
cancer 43.8 (95% CI 13.8-139.0), of cancers in upper digestive tissues 17.1 (95% CI 6.3-
46.5), of cancers in respiratory tissues (lung, bronchi, larynx) 15.6 (95% CI 5.4-46.0), of 
gynecological cancers 8.8 (95% CI 3.8-20.4) and of non-melanoma skin cancer 3.3 (95% CI 
1.0-10.7). In non-carriers there were no cases of pancreatic cancers or cancers in upper 
digestive tissues and one case of lung cancer, indicating a marked excess risk of these tumors 
in carriers compared to non-carriers from the same families.  
RRs of all non-melanoma cancers was significantly elevated in CDKN2A mutation carriers’ 
non-genotyped first-degree relatives (FDRs), 2.1 (95% CI 1.6-2.7) but not in second-degree 
relatives (SDRs), 1.0 (95% CI 0.8-1.4). In FDRs and SDRs, the relative risks were 
significantly elevated for pancreatic cancer and cancers in respiratory and upper digestive 
tissues. For these tumors, lower RRs were seen in SDRs compared to FDRs that in turn had 
lower RRs for these tumors than the genotyped carriers. 
When all p.Arg112dup family members (carriers, FDRs and SDRs) were compared to all 
controls, the following cancers had significantly higher RRs; melanoma, (RR 24.6), larynx 
(RR 21.8), pancreas (RR 13.9), esophagus (RR 5.4), tongue and oral cavity (RR 4.7), lung 
(RR 4.0), stomach (RR 2.5), breast (RR 1.7) and cervix (RR 1.5). 
Age specific cumulative incidence in carriers showed that at age 50, 20% had been diagnosed 
with non-melanoma cancers and 7% with cancers in pancreas, upper digestive and respiratory 
and tissues. At age 80, 76% had been diagnosed with non-melanoma cancers and 53% with 
tumors in pancreas, upper digestive and respiratory tissues. Of all 28 families in the study, 16 
(57%) families had cases of pancreatic cancer, 12 (43%) families had cases of cancers in 
respiratory tissues and 12 (43%) families had cases of cancers in upper digestive tissues.  
In ever-smoking carriers compared with never-smoking carriers, the odds ratio of cancers in 
pancreas, respiratory or upper digestive tissues was 9.3 (95% CI 1.9-44.7). The median age at 
end of follow-up of smokers that had been diagnosed with cancers in pancreas, upper 
digestive or respiratory tissues was 70 years while in smokers that had none of these 
diagnoses the median age at end of follow-up was 50 years. 
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7.2 RESULTS FROM PAPER II 
“CDKN2A mutation-negative melanoma families have increased risk 
exclusively for skin cancers but not for other malignancies” 
In CDKN2A wild type (wt) familial melanoma index cases (n=224) and their first-degree 
relatives (n=944), the prospective RR for melanoma was 56.9 (95% CI 31.4-102.1) and 7.0 
(95% CI 4.2-11.4) respectively. For all non-skin cancers combined, there were no 
significantly elevated risks in index cases or their relatives. Squamous cell skin cancers were 
the only non-melanoma tumors with significantly increased risks in either index cases (RR 
9.1, 95% CI 6.0-13.7) or first-degree relatives (RR 3.4, 95% CI 2.2-5.2). As in the previous 
study, basal cell carcinomas were not included since these tumors are not registered in the 
Swedish cancer Registry. To investigate if the increased risk seen for these cancers was a 
result of the participation in the preventive program with regular skin examination, a 
retrospective analysis of cancer risks before inclusion also was performed. This analysis 
showed that in both index cases and first-degree relatives the risks for squamous cell skin 
cancers were significantly elevated even before inclusion. 
Since no increases risks of non-skin cancers were found in the CDKN2A wt families, 
additional analysis was performed to explore if increased risks were present in families with 
young melanoma cases (<40 years old), multiple primary melanoma cases or >2 melanoma 
cases per family. It was found that families with young melanoma cases had a modest but 
statistically significant risk increase for non-skin cancers, RR 1.5, 95% CI 1.0-1.5, overall, 
but no individual tumor diagnosis was significantly increased. In families with cases of 
multiple primary melanomas or >2melanoma cases per family, no significant risk increase 
was found for non-skin cancers. 
A subset o the CDKN2A wt index cases (n=136) were analyzed for red hair color (RHC) 
variants in the MC1R gene. Allele frequencies were compared to a healthy Swedish control 
population described in an earlier study (n=663)204. At least one MC1R gene RHC variant 
(Asp84Glu, Arg151Cys, Arg160Trp or Asp294His) was found to be present in 33% of 
controls and in 54 % of the CDKN2A wt melanoma index cases (OR 2.4, 95% CI 1.6-3.4). 
Within the cohort of melanoma index cases, at least one RHC variant was present in 67% of 
cases with squamous cell skin cancers (OR 1.8, 95% CI 0.7-4.9), in 59% of multiple primary 
melanoma cases (OR 1.3, 95% CI 0.6-2.9) and in 54% of non-skin cancer cases (OR 1.0, 
95% CI 0.4-2.2). 
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7.3 RESULTS FROM PAPER III 
“Survival in familial melanoma cases carrying germline CDKN2A mutations: 
Increased mortality from melanoma and non-melanoma cancers compared to 
mutation-negative melanoma cases” 
Familial CDKN2Amut (n=104) and CDKN2Awt (n=444) melanoma cases were identified from 
31 CDKN2Amut and 238 CDKN2Awt melanoma families, respectively. CDKN2Amut cases were 
significantly younger than CDKN2Awt cases at the age of the diagnosis of first melanoma (40 
years vs. 50 years). Multiple primary melanomas were significantly increased in mutation 
carriers, 40% had multiple primary melanomas and 18% had 3 or more melanomas, 
compared to 15% and 4% in CDKN2Awt melanoma cases. There were no significant 
differences in body site, invasiveness or tumor thickness of melanomas between CDKN2Amut 
and CDKN2Awt melanoma cases. Non-skin cancers were significantly overrepresented among 
the CDKN2Amut cases; 38% were diagnosed with other tumors compared to 20% of the 
CDKN2Awt melanoma cases.  
At the censor date, 22% of CDKN2Amut and 13% of CDKN2Awt cases were deceased from 
melanoma and 17% of CDKN2Amut and 5% of CDKN2Awt cases were deceased from non-
melanoma cancers. Of the 31 mutated families, deaths from melanoma where seen in 18 
families (58%) and deaths from non-melanoma cancers in 12 families (39%). Of the 238 non-
mutated families, deaths from melanoma where seen in 53 families (22%) and deaths from 
non-melanoma cancers in 24 families (10%).  
All families except two have the Swedish founder mutation in CDKN2A (p.Arg112dup). A 
family with a p.Pro48Leu mutation in CDKN2A had deaths from both melanoma and non-
melanoma cancer. A family with a p.delAla60_Gly67 mutation in CDKN2A had no deaths 
from any cause among its two melanoma cases, but a death from pancreatic cancer in a 
carrier with no previous diagnosis of melanoma (and hence not included in this particular 
study where only melanoma cases were included).  
After adjusting for age, sex and tumor thickness, CDKN2Amut familial melanoma cases had, 
compared to CDKN2Awt cases, an increased mortality from all causes (HR 2.59, 95% CI 
1.76-3.78), from melanoma (HR 2.50, 95% CI 1.49-4.21) and from non-melanoma cancers 
(HR 7.77, 95% CI 3.65-16.51).Also, when compared to the matched sporadic cases, 
CDKN2Amut cases had significantly worse survival outcomes, while no significant differences 
were found between CDKN2Awt and sporadic cases.  
To assess if death rates from melanoma were affected by multiple primary melanomas or 
from diagnoses of non melanoma cancers, analyses were done by excluding all cases with 1) 
multiple invasive primary melanomas and 2) diagnoses of non-melanoma cancers. Both 
CDKN2Amut single melanoma cases and CDKN2Amut cases without any non-skin cancer 
diagnosis had significantly increased mortality rates from all causes, from non-melanoma 
cancers and from melanoma compared to CDKN2Awt single melanoma cases, both in the 
adjusted and in the unadjusted hazards models.  
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7.4 RESULTS FROM PAPER IV 
“Hereditary Uveal Melanoma: A Report of a Germline Mutation in BAP1” 
Next-generation exome sequencing was performed using peripheral blood derived DNA from 
the uveal melanoma proband, her younger sister and both parents (of which father was the 
obligate carrier). After mapping, and filtering of the variants likely to be artefactual, the 
remaining sequence variants were filtered to remove common SNPs and variants present in 
the mother. A frame-shift, truncating insertion, c.75insC in the BAP1 gene on chromosome 
3p21 was observed in the DNA from the proband and her father, but not in her mother or her 
sister. This frame-shift insertion results in a premature termination of the BAP1 protein in 
amino acid 43. In the uveal melanoma tumor of the proband, a microsatellite-based loss of 
heterozygosity (LOH) analysis was performed confirmed corresponding loss of the wild-type 
BAP1 locus allele.  
Sequencing of DNA from the uveal melanoma tumors from the proband’s paternal 
grandfather and his brother revealed the same BAP1 mutation in both tumors. Because of the 
very fragmented DNA, it was not possible to determine the presence or absence of LOH in 
the tumors.  
Among other family members, the mutation was also found in the grandfather’s dizygotic 
twin brother who was diagnosed with prostate cancer. As the prostatic carcinoma was an 
early minimal T1 lesion, analysis of BAP1 loss of heterozygosity (LOH) was not feasible. His 
children also carried the mutation, whereas the other tested non-affected family members did 
not have the mutation. The children of the twin brother with prostate cancer were found to 
have a high density of melanocytic nevi ranging from clinically benign to atypical. The 
atypical melanocytic nevi demonstrated a mild to moderate dyplasia histopathologically. One 
of the carriers was diagnosed with a preinvasive superficial spreading melanoma, which 
clinically appeared as an oval-shaped orange-red plaque with slight pigmentation only 
visualized in the dermoscope. Histopathologically, the melanoma harbored atypical 
melanocytes throughout epidermis lacking features of a Spitz-like tumor, as well as 
regression of 0.5 mm but no ulceration. 
Individuals belonging to three other kindreds with uveal melanoma were screened in the 
complete coding region of BAP1without any findings of mutations. 
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8 METHODOLOGICAL CONSIDERATIONS 
8.1 SELECTION BIAS 
Selection bias is a systematic error in a study that stems from the procedures used to select 
subjects and from factors that influence study participation205. Studies of hereditary disease 
can be subject to ascertainment (sampling) bias, a form of selection bias. Ascertainment bias 
can occur when ascertainment of the most severely affected individuals and families is 
favored, leading to the interpretation that the condition studied, is more severe than it actually 
is. In Papers I-III, CDKN2A mutation testing has been performed in familial melanoma 
kindreds, identified in families with multiple cases of melanoma and not sampled from the 
general population. For this reason, estimations of effects of the CDKN2A mutation could be 
biased compared to if CDKN2A mutation carriers had been sampled from the general 
population. Phenocopy is sometimes observed in families carrying a disease associated 
mutation and occurs when a disease that is associated with a certain mutation is also seen 
among non-carriers of the mutation in the same family. In CDKN2A mutated families, a 
certain risk increase of melanoma is seen, also among non-carriers of the CDKN2A mutation, 
indicating that some degree of ascertainment bias could be present. The families with 
CDKN2A mutations that are identified could have other melanoma risk modifying factors, 
such as pigmentation traits, UV exposures and other risk modifying gene variants that 
increase their melanoma risk. Ascertainment bias could result in CDKN2A mutation carriers’ 
risks for melanoma being overestimated. Paper IV, which essentially is a case study of a 
novel gene variant in a rare uveal melanoma family is by its nature subject to selection bias. 
However, in the study of inherited disease, reports of novel genetic associations often involve 
few cases where later studies will corroborate or challenge such associations. In the case of 
the BAP1 mutation, concurrent and later studies have indeed supported the association of 
BAP1 and hereditary uveal melanoma148,191,193,206.  
Another concern regarding selection bias is the accrual of controls and familial cases. While 
controls are sampled from the Population Registry, familial cases are sampled from 
preventive programs with the aim to prevent and detect skin cancers at earlier stages. The 
effect of this preventive program is that skin cancers are more likely to be detected than in 
those that are not in a preventive program. Also, participants in preventive programs could be 
more likely to take other preventive measures, such as reducing their exposures from known 
carcinogens and participate in screening of other cancers. In Papers I-III the following factors 
are likely to reduce the occurrence or the effect of a selection bias. 
I. The frequency of CDKN2A mutations in the normal population is low, in a Swedish 
study, the mutation was found in none of 663 healthy control subjects and in one of 
526 sporadic melanoma cases and in nine of 200 familial melanoma cases48. This 
indicates that CDKN2A mutations are indeed mostly confined to familial melanoma 
cases.  
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II. In Sweden, the accrual of melanoma families is population based, since all new 
melanoma cases in the population should, according to national clinical guidelines, be 
questioned regarding relatives with melanoma and if this is the case, be offered 
participation in a preventive program. The accrual of subjects for CDKN2A mutation 
testing that has been done for the purpose of study, has been more biased, i.e. with 
highest participation among cases from Lund and Stockholm. 
III. Melanoma risk is always shown prospectively from a date when the first blood 
sample was taken for CDKN2A analysis, which is the date when the family was 
identified for study. 
IV. In CDKN2A wt kindreds, a high riks for squamous-cell skin cancers was found. This 
could possibly be related to the fact that melanoma kindreds are enrolled in a 
preventive program with regular skin exams, resulting in higher rates of detected skin 
cancers. For this reason, a retrospective analysis was also done to evaluate the risk of 
squamous cell skin cancers, before families were identified. This retrospective 
analysis showed that the risk increase for non-melanoma skin cancers was also 
present before inclusion. Interestingly, in CDKN2A mutation carriers, high risks of 
non-melanoma cancer were seen, but not of squamous-cell skin cancers, despite the 
fact that all family members had patricipated in the same preventive program. 
V. The main aim of Paper I-II was to assess the non-melanoma cancer risk. In the 
preventive program or for the CDKN2A mutation analysis, there has been no 
inclusion critera regarding other cancers than melanoma, but families with other 
cancer cases could have been more inclined to participate in preventive programs and 
donate blood for study. Also for other cancers, prospective risks are shown.  
VI. In the study of cancer risk in CDKN2A mutation carriers, cancer incidences were 
compared, both to population controls and also to non-carriers from the same 
families, that also participated in the preventive program. Compared to both control 
groups the prospective risk for melanoma and other cancers was significantly 
increased.  
VII. In Paper III, the aim was to evaluate wheather CDKN2A mutation carriers had 
different survival following a melanoma diagnosis, compared to non-mutation 
carriers.To avoid selection bias, CDKN2A wt familial melanoma cases were selected 
as controls, since they had the same follow-up within a preventive program as 
CDKN2A mutation carriers. However, if they were suitable controls could be 
questiones since they have unknown underlying causes for increased melanoma 
suceptibility. For this reason, also, matched sporadic melanoma cases from The 
Stockholm-Gotland Melnoma Regerstry were used as controls, but with the 
awareness that this group has not had the same follow-up.  
8.2 INFORMATION BIAS 
Information bias (misclassification) is a systemic error in a study that can arise if the 
information collected about or from study subjects is erroneous205. Misclassification can 
occur when data on subjects and controls are collected directly from the study participants 
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themselves or gathered by the researcher. Individuals from melanoma families might, 
compared to individuals with no family history, be more prone to report other cancers 
diagnosed among themselves or their relatives. If cancers in relatives only would have been 
gathered from index persons, information on existing relatives and their diagnoses could have 
been left out. Also, researchers could have more clinical or pathology reports available for 
family members that are followed-up at their clinic, than in a healthy control population. All 
these scenarios would result in differential misclassification that could lead to an over- or 
underestimation of an effect-outcome association. In Papers I-III, the effect of 
misclassification has been reduced by the usage of nation-wide, high quality registries, with 
the identification of all first- and second-degree relatives attained from the Swedish Multi-
generation Registry and all cancer diagnoses attained from the Swedish Cancer Registry and 
all vital events (births, deaths) from the Population Registry.  
8.3 CONFOUNDING 
Confounding is a systemic error that arises when an association between an exposure and an 
outcome is being studied, but the exposure and outcomes are both associated with a third 
variable, that is not an intermediate link between the two. There are different methods used to 
prevent confounding, such as matching, randomization, stratification or restriction of study 
cases. Regression analyses can be applied if confounders are known and accounted for. For 
cancer risks, age and gender are strongly associated variables. In Papers I-II, confounding due 
to age and gender was prevented by matching for these variables. For prognosis, age, gender 
as well as tumor stage are strongly associated variables. In Paper III, confounding due to 
these factors was prevented by the utilization of adjustments in the Cox proportional hazards 
regression model. Residual confounding occurs when there is remaining confounding after 
matching and adjustments have been performed, i.e. due to unknown confounding factors. In 
none of the papers there was any data included on factors that affect cancer risks and/or 
prognosis, such as socio-economic status, UVR exposures or smoking that are all factors that 
can differ between population based controls and familial melanoma kindreds participating in 
a preventive program.  
8.4 VALIDITY 
The internal validity refers to the quality of the study design and depends on that sources of 
systematic error, as those mentioned above are minimized. The external validity is the extent 
to which the results of a study can be generalized to other situations and to other populations. 
The external validity is highly dependent on the internal validity. In Paper I, all CDKN2A 
mutation carriers are carriers of the Swedish founder mutation p.Arg112dup. Findings from 
previous studies have demonstrated that cancer risks can differ between different mutations in 
the CDKN2A gene, hence the validity of the finding for carriers of other CDKN2A mutations 
is uncertain. Sweden and the Netherlands are the two countries with the largest known 
CDKN2A founder mutation populations. Both the Swedish and the Dutch (Leiden) CDKN2A 
mutations are located in the exon 2 of the gene, and both are set in ankyrin repeats 3–4 of the 
gene. Previous study of the Leiden mutation have shown similar spectra of tumors as in the 
48                                                           
    
 
Swedish founder mutation carriers and a later study also showed an association with tobacco 
smoke166.  
8.5 RANDOM ERROR AND PRECISION 
The error that remains after systematic errors are eliminated is called random error. Random 
error arises due to measurement errors or from sampling variability. By increasing the sample 
size, by repeating measurements or repeating the study, random error is reduced and precision 
increases. Random errors are reflected in p-values and confidence intervals. In Papers I-III 
the precision is affected by the fact that familial melanoma cohorts are rather small, in 
particular the cohort of CDKN2A mutation carriers. This, of course has to be regarded in the 
light of the rarity of CDKN2A mutations in the population. Also the occurrences of cancers 
are highly increased in mutation carriers compared to the normal population, with increased 
numbers of outcome events and in turn increasing precision. In Paper I, the precision of the 
estimated cancer risks in mutation carriers, is increased by repeating analyses in different 
cohorts of carriers, first in confirmed carriers, then in first-degree relatives (approximately 
50% carrier frequency) and next in second-degree relatives (approximately 25% carrier 
frequency). In CDKN2A mutation carriers, significant risk increase for cancers in respiratory 
and upper digestive tissues were seen in all cohorts, being highest in carriers, followed by 
first- and second-degree relatives, indicating a gene-dose effect.  
8.6 POWER 
Statistical power is the likelihood that a study will detect an effect when there is an effect 
there to be detected. Statistical power is affected chiefly by the size of the effect and the size 
of the sample used to detect it. Bigger effects are easier to detect than smaller effects, while 
large samples offer greater test sensitivity than small samples. In the planning of Study I, it 
was estimated that the optimal size of an age- and sex-matched control group for the 
CDKN2A mutation carriers would be three controls for every carrier. When data analysis 
started it became clear that in the controls, for several cancer diagnoses, there were none or 
only rare occurrences. This had the consequence that relative risks of several cancer types 
were non-calculable and interpretations of risks uncertain. To increase power of the analysis, 
the control groups of carriers, their first- and second-degree relatives were combined. This 
was done at the cost of the matching being disturbed, possibly increasing confounding, 
however in the prespecified control groups the age and sex distributions were similar to the 
combined control group.  
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9 CONCLUSIONS, DISCUSSION AND IMPLICATIONS 
9.1 CONCLUSIONS, DISCUSSION AND IMPLICATIONS OF PAPER I 
“High Risk of Tobacco-Related Cancers in CDKN2A Mutation-Positive 
Melanoma Families" 
The main finding of this study is that the Swedish founder mutation in CDKN2A 
(p.Arg112dup) is associated with high risks of tobacco-related cancers in respiratory and 
upper digestive tissues, including pancreas. Upper digestive tissues and respiratory tissues 
have a common origin from foregut endoderm101 and are known to be sensitive to exposures 
from certain carcinogens. In particular strong associations with cancers in these tissues and 
tobacco smoke and/or alcohol have been established46,207. In a study of mutational processes 
in multiple human cancers, it was reported that of the 30 different tumor types analyzed, 
melanoma, lung, esophageal, head and neck and gastric cancers were all among the tumor 
types with the highest numbers of acquired mutations45. Digestive and respiratory organs are 
highly exposed to multiple carcinogens in our environment in analogy to the skin being 
exposed to ultraviolet (UV) radiation. It has been shown that melanoma penetrance in 
CDKN2A mutation carriers is associated with the environmental UVR exposure in the 
country of residence, supporting the impact of environmental factors in genetically 
predisposed individuals 58. In melanoma tumors, UVB signature DNA changes are 
commonly observed in the CDKN2A gene 110. Somatic CDKN2A alterations are frequently 
observed in pancreatic, lung, head and neck, esophageal and gastric cancers, where they are 
believed to be driver mutations 208-211. In lung and head and neck cancers it has been shown 
that somatic alterations in the CDKN2A gene are associated with tobacco smoke and/or 
alcohol exposure 212-214. Further, in a CDKN2A knockout mouse model, where both p16 and 
the murine homolog of p14ARF are eliminated, it was demonstrated that the cancer risk that 
was already very high in the knock-out compared to wt mice, was multiplied by adding the 
potent carcinogen 9,10-dimethyl-1,2-benzanthracene (DMBA). Notably, no such multiplicity 
effect was seen in the wt mice by adding the carcinogen215. Germline mutations in both TP53 
and RB1 gene are associated with high risks of lung cancer122,123. In both RB1 and TP53 
mutation carriers, the elevated risks for lung cancers are mainly observed in smokers 123,216. 
Thus, it seems that carriers not only of CDKN2A mutations, but also of mutations in tumor 
suppressors in the same pathways as p16 and p14-ARF, are at elevated risks of smoking-
induced cancers.  
In upcoming, updated Swedish guidelines on familial melanoma there are several novel 
recommendations that are based on the findings from this study. In particular, CDKN2A 
mutation carriers are recommended follow-up, not only for melanoma, but also oncologic 
follow-up for non-skin cancers. Carriers should at an early age be informed about the very 
high risks associated with smoking and offered cessation aids if they are already smokers. 
Further, it is recommended that CDKN2A mutation carriers should biennially undergo 
abdominal MRI and low-dose thoracic CT scans aimed at detection of premalignant or earlier 
stages of cancer.  
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9.2 CONCLUSIONS, DISCUSSION AND IMPLICATIONS OF PAPER II 
“CDKN2A mutation-negative melanoma families have increased risk 
exclusively for skin cancers but not for other malignancies” 
The main finding of this paper is that familial melanoma cases with no mutation in the 
CDKN2A gene have high risks for melanoma and squamous cell skin cancers, but no 
increased risks of other cancers. Our findings of high risks of skin cancers and no increased 
risks of other cancers in CDKN2A wt melanoma families, in combination with the increase 
observed in RHC variants in the MC1R gene, are consistent with the possibility that in the 
majority of these families, there are not mutations in high-risk cancer predisposing genes, but 
rather a segregation of variants in low-risk genes. Melanomas and squamous cell skin cancers 
are highly associated with increased UV-exposure and it is possible that shared 
environmental exposures, i.e. similar sun habits, also contributes to increased risks of both 
classes of skin tumors within families217. Importantly, although no increased risk of non-skin 
cancers were observed in CDKN2A wt melanoma families, there may be families carrying 
high-risk cancer predisposing gene mutations that are masked under the majority of families 
that do not carry such mutations. Further genetic studies are essential to identify new 
melanoma associated genes. Our study shows that families with young melanoma cases have 
higher risks for non-skin cancers, indicating that such families could be more likely to carry 
high-risk mutations.  
This study has, together with Paper I several clinical implications. Presently, the international 
melanoma genetics consortium (GenoMEL) and most national clinical practice guidelines 
recommend that CDKN2A testing should be conducted merely in a research setting90,218, 
however, strong argumentation for clinical CDKN2A testing has been put forward219. Our 
findings further justify CDKN2A mutation testing of melanoma family members in the 
clinical setting where the mutation status should determine the follow-up routines in affected 
families. Members of CDKN2A wt melanoma families require counseling and screening 
aimed at prevention and earlier detection of skin cancers while CDKN2A mutation carriers 
require in addition to dermatologic surveillance, also follow-up for non-skin cancers. In the 
upcoming, updated Swedish guidelines on familial melanoma these recommendations are 
included. 
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9.3 CONCLUSIONS, DISCUSSION AND IMPLICATIONS OF PAPER III 
“Survival in familial melanoma cases carrying germline CDKN2A mutations: 
Increased mortality from melanoma and non-melanoma cancers compared to 
mutation-negative melanoma cases” 
The main finding of this paper is that CDKN2A mutation carriers have, compared to non-
carriers, significantly worse melanoma-specific survival, which is independent of age, 
gender, tumor thickness and diagnoses of multiple primary melanomas or of non-melanoma 
cancers. These results indicate that the CDKN2A germline mutation is directly associated 
with a more aggressive melanoma phenotype, but the mechanism for this is unclear. In a 
recent study, it was demonstrated that primary melanomas from CDKN2A mutation carriers 
do not exhibit a distinct gene expression signature compared to sporadic melanomas. Also 
frequencies of BRAF or NRAS mutations do not seem to differ in CDKN2A mutation carriers 
and non-carriers185,186. Still, somatic losses of CDKN2A have been associated with worse 
outcomes in melanoma72,73,220 and also in various other cancers (gliomas, sarcomas, certain 
leukemias and lymphomas, lung, oral, gastroesophageal, renal cell, pancreatic, breast, 
bladder, hepatocellular cancers)221-233. As mentioned previously, CDKN2A mutation carriers 
appear to be more sensitive to carcinogenic/mutagenic exposures. It is possible, that germline 
and somatic mutations in the CDKN2A gene that lead to a disruption of proper cell cycle 
inhibition functions of the p16/p14ARF proteins permit cells with additional acquired 
mutations to progress through the cell cycle. This may result in an accumulation of 
carcinogen-induced mutation in tumor cells, contributing to greater tumor aggressiveness.  
This study shows that CDKN2A carriers, not only need thorough surveillance to prevent and 
detect melanomas at earlier stages, carries also need close follow-up for melanoma 
recurrences. Earlier detection of stage III-IV melanoma will hopefully lead to better survival 
in this group, especially considering the landscape of effective melanoma regimens emerging. 
Activating BRAF mutations are at least as common in melanomas from CDKN2A mutation 
carriers as in sporadic melanomas185,186, and such tumors may therefore be candidates for 
BRAF inhibitor-based therapies. Among BRAF mutation positive melanoma cases receiving 
BRAF inhibitor therapy, somatic loss of CDKN2A has been associated with worse 
outcomes234, but this might reflect the generally worse prognosis associated with CDKN2A 
loss, rather than a specific association with worse response to BRAF inhibitors. Also, 
preclinical studies indicate that CDKN2A mutations may predict sensitivity in melanoma 
patients to CDK4/6 inhibitors that are emerging as promising novel kind of agents in various 
cancers235,236. Further, a recent study demonstrated that increased mutational load and 
specifically presentation of neo-antigens was associated with better response to CTLA-4 
immune checkpoint inhibition237. If melanomas in CDKN2A carriers have, in line with our 
findings, increased mutational load, such tumors might have a beneficial response to immune 
checkpoint blockade. 
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9.4 CONCLUSIONS, DISCUSSION AND IMPLICATIONS OF PAPER IV 
“Hereditary Uveal Melanoma: A Report of a Germline Mutation in BAP1” 
The main finding of this study is the identification of a novel mutation in the BAP1 gene 
segregating with familial cases of uveal and cutaneous melanoma. Loss of heterozygosity in 
the tumor material further supports the role of BAP1 germline mutation as a causative factor 
for uveal melanoma. The identified mutation truncates the gene, obliterating most of the 
protein, including the binding domains to BRCA1, BARD1 and HCF1 and the active nuclear 
ubiquitin carboxy-terminal hydrolase domain. In Sweden, additional three families, all with 
different mutations in the gene (two truncating and one non-synonymous) have been 
identified.  
Germline mutations in the tumor suppressor gene BAP1 has been associated with the 
development of various malignancies in predisposed families and the condition has been 
named the BAP1 tumor predisposition syndrome (BAP1-TPDS). In a recently published 
comprehensive review of 27 reports of germline BAP1 mutation families, mutations were 
seen at different gene loci and mutation site or type was not associated with any particular 
cancer type148. In this study 31% of carriers had a diagnosis of uveal melanoma, 22% of 
mesothelioma, 13% of melanoma, 10% of renal cell cancer and 6% of basal cell cancers. The 
penetrance of cancers among BAP1 mutation carriers was estimated to 85%. Notably, 72% 
were identified with distinct subset of benign skin lesions. A range of names has been given 
to these lesions, including melanocytic BAP1-mutated atypical intradermal tumors, atypical 
Spitz tumors, BAPomas or Wiesner nevi. These lesions are well-circumscribed dome shaped, 
skin-colored or reddish-brown nodules,with average sizes of 5 mm, and range widely in 
number. Morphologically, the lesions are mostly intradermal with occasional involvement of 
the junctional epidermis,and show cytological features resembling atypical Spitz nevi. They 
are characterized by biallelic inactivation of BAP1 and frequent BRAFV600E mutation. 
These lesions are believed to be potential precursors of melanomas in carriers. Accordingly, 
verified BAP1 carriers require close follow-up for uveal and cutaneous melanoma as well as 
for other cancers.  
The findings in Paper IV are based on the identification of one single family with an unusual 
hereditary disposition for uveal melanoma and on the availability of next-generation 
sequencing techniques. To conclude, this study shows that collaboration between clinicians 
and laboratory researchers has the potential to generate novel translational findings.  
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10 FUTURE PERSPECTIVES 
10.1 BIOLOGICAL DIFFERENCES IN TUMORS FROM CDKN2A MUTATION 
CARRIERS AND NON-CARRIERS 
The findings of sensitivity to carcinogens as well as worse prognosis in CDKN2A mutation 
carriers raises the question if tumors from CDKN2A mutation carriers have biological 
differences compared to tumors from non-carriers. Previous studies have found no 
differences in frequencies of BRAF or NRAS mutations or in RNA expression signatures, 
depending on germline CDKN2A mutation status185,186. In this aspect it would be of interest to 
explore other potential biological differences, such as mutational load in melanomas and 
other tumors from germline CDKN2A mutation carriers and non-carriers respectively, in 
particular mutations with carcinogen signatures. In addition to genetic changes, epigenetic 
events have emerged as key mechanisms in the development and progression of human 
cancer and could also potentially differ between CDKN2A mutation carrier´s and non-
carrier´s tumors. In the study on expression signatures by Jönsson et al. it was found that the 
more beneficial “high-immune” signature was present in 27% of melanomas from sporadic 
cases, but only in 9% of melanomas from CDKN2A mutation carriers. Hence, it would also 
be interesting to investigate if immunohistochemistry specified immunophenotypes differ in 
tumors from CDKN2A mutation carriers and non-carriers. 
10.2 PROSPECTIVE STUDY OF OUTCOMES IN CDKN2A MUTATION 
CARRIERS 
In Sweden, the CDKN2A mutation test will soon be implicated as a clinical test in melanoma 
families, where melanoma families are defined as families with at least two first-degree 
relatives with melanoma or tree or more diagnoses of melanoma or pancreatic cancer in blood 
related individuals. In upcoming Swedish guidelines, CDKN2A mutation carriers will receive, 
bedsides from dermatologic surveillance, also oncologic follow-up and information to 
promote abstinence from tobacco smoke and smokers will get professional help to quit. 
Carriers will also be offered MRI and CT screening for pancreatic and lung cancers, 
respectively. Optimally, these interventions should be followed-up in a prospective study, i.e. 
by offering intervention to both members of CDKN2A mutated and non-mutated melanoma 
families. Bearing in mind that known carriers are few (in Sweden ~100 known alive carriers) 
such study could take many years to complete. It would therefore be more efficient if such a 
study would be conducted as a multi-center study i.e. by the GenoMEL consortium. Also a 
multi-center approach should be applied to assess therapy responses of CDKN2A mutation 
carriers, in particular to the novel immune based and targeted therapies.  
10.3 SCREENING OF MUTATIONS IN FAMILIAL MELANOMA CASES 
In melanoma families, mutations other than CDKN2A have so far only been identified in rare 
families. As no gene, other than CDKN2A, has been identified in any substantial portion of 
families, it is likely that in the CDKN2A wt families, there are quite many different genetic 
underlying causes for melanoma heredity. A recent study identifies 20 different melanoma 
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susceptibility loci, whereof five have not been described previously 238. In our group we plan 
to initiate a next generation sequencing gene panel, involving both known high- and low-risk 
melanoma genes (Table 6, p. 18),that is continually updated along with new findings of 
melanoma predisposing genes. Families where no mutations or variants are found in known 
genes should be enrolled in exome or genome sequencing studies and to increase power, 
multi-center studies are preferable.  
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